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Abstract 
 
 
The potential for nitric oxide (NO) metabolites (e.g. inorganic nitrite) to act as stable stores of 
“Transported Nitric Oxide” has excited huge interest due to the substantial potential therapeutic 
avenues.  The prospect developing of a “silver bullet” that could target areas most in need of 
vasodilatation, by releasing NO in areas of hypoxia and ischaemia, could prove a massive advance in 
the treatment of vascular disease. 
In this thesis I examine the effects of nitrite infusion in both hypoxia and normoxia.  I examine the 
effects both in health and heart failure, and investigate the potential roles of Nitric Oxide Synthase 
(NOS) and Xanthine Oxidase (XO) in mediating the reduction of nitrite. 
We found, and were the first to report in man, that intra-arterial infusions of nitrite had little effect 
upon the vasculature in high oxygen tension environments but led to significant vasodilatation during 
hypoxaemia. We found that patients suffering with Chronic Heart Failure responded differently to 
nitrite infusion to healthy controls, possibly as a result of differences in redox-stress.  In healthy 
volunteers, at rest, neither NOS nor XO appeared to play a significant role in nitrite induced 
vasodilatation in normoxia and mild hypoxia. 
We found that vascular myoglobin contributes to the reduction of nitrite to nitric oxide and may play a 
role in prolonging the vasodilatation induced by nitrite infusion. 
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Chapter 1 - Introduction 
 
 
Transported Nitric Oxide and Hypoxic Vasodilatation 
– Evolving concepts and Contending theories. 
19 
 
1.1 Introduction 
 
The ability of the body to match perfusion to the demands of a particular tissue bed is highly 
conserved and involves an extremely efficient system for harmonizing delivery of blood to the local 
requirements.  This phenomenon has been well described and studied. There remained, however, a 
‘missing link’ in this mechanism which led to the development and description of a new paradigm – 
that of ‘Transported Nitric Oxide’.  It is this paradigm that I have investigated in the studies presented 
in this thesis.   
This new concept excited huge interest due to the substantial therapeutic avenues that were opened.  
The potential for the development of a “silver bullet” that could target areas most in need of 
vasodilatation could prove a massive advance in the treatment of vascular disease. 
In this chapter I will aim to review the current literature in this field and to examine the current 
understanding of the mechanisms that underpin this phenomenon.  In particular I will focus on the 
potential roles of inorganic nitrite and haemoglobin bound Nitric oxide in mediating this effect and 
the therapeutic opportunities that are being investigated. With this background presented I will then 
describe the series of studies that I have performed and discuss how these studies will advance our 
understanding of nitrite physiology. 
 
1.2 Hypoxic Vasodilatation 
 
The ability of vessels and more specifically, arterioles to vasodilate as a consequence of downstream 
tissue hypoxia is a phenomenon that has been recognised for over a century
1
.  Traditionally this was 
felt to be due to the release of local mediators as a result of increased metabolic activity
2
.  These 
mediators include potassium, adenosine and prostacyclin
1
.  Hypoxic vasodilatation still occurs, 
however, even after the blockade of these ‘traditional’ mediators3.  It has been postulated that NO may 
be transported in the bloodstream to areas of low oxygen tension where it is released causing 
vasodilatation
4, 5
.   
20 
 
1.3 The Paracrine Role of Nitric Oxide ( NO) and NO generation 
 
Since the discovery of nitric oxide (NO) as EDRF  in the 1980’s 6, 7 NO has emerged as an important 
cellular messenger molecule and has been implicated as a physiological and pathophysiological 
molecule in the cardiovascular, immune and nervous system 
8
. NO is produced by various types of 
cells and is thought to be associated in a wide range of disease processes, exerting both beneficial and 
detrimental effects at the cellular and vascular levels
9
  
 
Vascular NO is released from the endothelium in response to shear stress or agonists, such as 
acetylcholine, and is formed from L-arginine..  The NO thus formed diffuses across to the vascular 
smooth muscle inducing vascular relaxation.  The process is mediated by a family of complex 
enzymes: the Nitric Oxide Synthases  (NOS)
10
.  Several co-factors are required for the unusual five 
electron oxidation of one electron of the L-arginine guanidino group. 
11
  These cofactors include 
Nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), 
Flavin mononucleotide (FMN) and Tetrahydrobiopterin (BH4).  12 
 
L-arginine + n NADPH + n H
+
 + m O2 → citrulline + nitric oxide + n NADP
+
 
 
NOS are very well conserved being found in all eukaryotes.  NOS was first described is 1989
13
 and 
are not ATP dependent.     Three isoforms of NOS have been identified.  Endothelial (eNOS), 
inducible (iNOS) and neuronal (nNOS). This family of enzymes catalyses the conversion of L–
arginine to L-citrulline forming NO in the process. A distinction was initially made between iNOS 
and eNOS/nNOS.  iNOS was felt to be ‘induced’ in response to inflammatory and immunomodulatory 
stimuli whereas eNOS and nNOS were felt to be ‘constitutively’ expressed.  It has since become 
apparent that the gene expression of both eNOS and nNOS can also be affected by stimuli such as 
haemodynamic shear stress (in the case of eNOS).  This nomenclature is now used to reflect the tissue 
of origin for the original DNA and protein isolates.  Although eNOS was originally isolated and 
21 
 
cloned from vascular endothelium its expression has been described in blood platelets, cardiac 
myocytes and hippocampal neurons. 
 
iNOS and nNOS are soluble and found predominantly in the cytosol, while eNOS is 
membrane associated. 
nNOS was first isolated in the mammalian brain
14
 but its role in cardiac function has since 
been described.  nNOS activity is primarily regulated by increases in intracellular Ca2+, 
which activate nNOS through calmodulin binding 
15
.  The biological actions of NO rely upon 
the association of nNOS with speciﬁc protein complexes. These physical interactions with 
nNOS allow the integration of NO signalling into distinct transduction cascades.  
In health eNOS has been found to reside primarily in the sarcolemma caveolae and 
endothelial cells whereas nNOS has been found to be associated with the ryanodine receptor 
(RyR) in the sarcoplasmic reticulum
16
.  These specific locations may play a role in excitation-
contraction coupling.  In heart failure this relationship is altered.    Damy and colleagues
17
 
examined the expression and localisation of NOS in health and heart failure.  The 
myocardium of explanted hearts from patients who had undergone cardiac transplantation 
was compared with individuals who had died from head trauma or intracranial bleeds.  The 
myocardium from patients with heart failure displayed increased nNOS mRNA and protein 
expression.  The activity was associated with a translocation of nNOS to the sarcolemma via 
interactions with caveolin 3.  This increased nNOS activity appeared to counterbalance a 
decrease in the activity and expression of eNOS
17
. 
NO generated by eNOS diffuses into adjacent vascular smooth muscle cells where NO 
activates guanylate cyclase, which induces smooth muscle relaxation by a variety of 
22 
 
mechanisms. Firstly, increased intracellular cGMP inhibits calcium entry into the cell, and 
decreases intracellular calcium concentrations. Secondly, activation of K
+
 channels leads to 
hyperpolarization and relaxation.  cGMP also stimulates a cGMP-dependent protein kinase 
(cGK) that activates myosin light chain phosphatase, the enzyme that dephosphorylates 
myosin light chains, which leads to smooth muscle relaxation.
18
 
cGK also  phosphorylates specific target proteins such as the 46/50-kDa vasodilator-
stimulated phosphoprotein (VASP), the IP3receptor and associated proteins, phospholamban, 
rapB1and the myosin binding subunit of myosin phosphatise
19, 20
.  
In platelets, vascular smooth muscle cells, endothelial cells, and fibroblasts, VASP is 
concentrated at and associated with actin microfilaments, focal adhesions, and cell-cell 
contacts 
21, 22
 VASP appears to be an important modulator of microfilaments and regulates 
spatially confined actin polymerization
23
.  
In the vasculature the exact function of VASP remains to be ascertained. Three cGK 
phosphorylation sites on VASP have been identified in vitro and in intact platelets: serine 
157, serine 239, and threonine 278. 
24, 25
  
 
 
NO also diffuses into the vessel lumen where this highly reactive radical readily forms 
various NO metabolites.  Whereas these ‘metabolites’ were previously considered ‘metabolic 
dead-ends’, they are now the focus of considerable attention. 
The understanding of the role of NO in human biology has evolved from it being considered 
a simple vasodilator to being seen as an important and complex cellular signalling molecule 
with a vast array of biological functions.   
23 
 
NO appears to play an important role in modulating ischaemia-reperfusion injury(IRI).  Jones 
and colleagues showed that eNOS deficient mice have increased infarct size following 
myocardial IRI 
26
.  In the light of this, numerous strategies and various exogenous 
pharmacological agents designed to manipulate NO have been examined. Exogenous 
administration of NO donors (e.g DETA-NO and SNAP) prior to, during or at reperfusion 
reduces infarct size and endothelial dysfunction
27
.  
The role of NO in the setting of acute ischaemia appears to be a double edged sword. While 
the studies quoted above support a protective role for NO when released at relatively low 
levels, higher concentrations have been shown to be harmful.  
During severe ischaemia and infarction, the generation of superoxide and nitric oxide in 
endothelial cells results in the release of inflammatory mediators (e.g. platelet-activating 
factor, tumour necrosis factor).  This increases the synthesis of adhesion molecules that 
mediate leukocyte-endothelial cell adhesion.  The release of these inflammatory mediators, 
following reperfusion, appears to activate endothelial cells in remote organs that are not 
exposed to the initial ischaemic insult. The remote response to ischaemia-reperfusion results 
in leukocyte-dependent microvascular injury that is often seen in multiple organ failure.
28
 
How exactly NO protects against IRI remains unclear and several mechanisms have been 
proposed e.g. inhibition of influx through L-type calcium channels, activation of sarcolemmal 
and mitochondrial KATP channels, antioxidant effects, activation of cyclooxygenase- 2 with 
production of cytoprotective prostanoids, and inhibition of proapoptotic proteins
29
. Currently, 
the role of NO in inhibiting cytochrome c oxidase on the electron transport chain thereby 
decreasing mitochondrial respiration and limiting oxygen consumption is an area of intense 
research and could hold important information about how NO exerts a beneficial effect 
following IRI. 
24 
 
Furthermore, NO also plays an important role in maintaining and encouraging blood flow by 
decreasing platelet aggregation and adhesion which may contribute to the protective effect of 
NO in IRI 
30, 31
. 
 
In this context NO generated in an ischaemic environment can  inhibit cytochrome c oxidase on the 
electron transport chain thereby decreasing mitochondrial respiration and limiting oxygen 
consumption.  This then leads to decreased cellular damage.  
NO also plays an important role in maintaining and encouraging blood flow by decreasing platelet 
aggregation and adhesion.   
 
 
1.4 NO Metabolites 
 
There has been extensive investigation into the relative importance of different NO stores (described 
below) and of the physiological importance (or otherwise) of NO released from these stores.  NO is 
highly reactive and either rapidly exerts its physiological effect upon the underlying vascular smooth 
muscle or reacts to form NO metabolites such as HbNO, Nitrite and Nitrate.  (Figure 1.1) 
 
Figure 1.1  - NO metabolites in plasma and RBCs 
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NO has a very high affinity for heme groups
32
 and reacts with oxyhaemoglobin to form 
methaemoglobin and nitrate.  NO reacts with thiol (SH) containing amino acids, peptides and proteins 
to from S-nitrosothiols.  These S-nitrosothiols include S-nitroso-albumin, S-nitroso-haemoglobin, S-
nitroso-L-cysteine and S-nitroso-L-glutathione amongst others.  There has been significant interest in 
these S-nitrosothiols, some holding that these metabolites act as the main store of transported NO and 
in particular it has been postulated that NO bound to haemoglobin (Hb) may act as this reservoir of 
NO
33
.  Moreover, it has been suggested by Stamler and colleagues that the Hb molecule acts as both 
oxygen “sensor”, in that it undergoes a conformational change when deoxygenated, as well as a NO 
reservoir
34
.  Although Hb does not act as a sensor in the traditional sense its structural response to 
abmient oxygen tension has led to it being described in these terms.  It is proposed that this 
conformational change allows the release of NO from Hb and hence delivery to the hypoxic tissue by 
this allosteric mechanism.  In this model, as blood passes through the pulmonary circulation NO binds 
to deoxyhaemoglobin to form Hb-Fe(II)NO.  During oxygenation NO is transferred to the highly 
conserved ß chain cysteine 93 residue of Hb to produce S-nitrosylhemoglobin (SNO-Hb).  In 
hypoxaemic conditions the conformational change that Hb undergoes results in NO being transferred 
and some released in the process leading to vasodilatation
35
. (Figure 1.2) 
 
 
Figure 1.2 – Hb structure in high and low oxygen tension environments 
26 
 
 
1.5 Limitations of the HbSNO theory 
 
In this model of NO transport, haemoglobin acts as both sensor of ambient oxygen tension and carrier 
molecule for the delivered NO.  While inherently attractive this model has potential limitations.  It has 
been suggested that the concentration of HbSNO in vivo is too small to produce a significant 
physiological effect
36
.  This has been countered by the argument that while the levels may be 
relatively small this does not preclude a physiologically important role since the minute, picomolar, 
concentrations of NO allow a critically important role to be played by this key molecule.
37
 
Differences exist over the relative concentration of HbSNO across the circulation.  Proponents of the 
HbSNO model reported arterio-venous gradients of HbSNO which was felt to be supportive of a role 
for haemoglobin in NO transport. 
4
  Others, however, have failed to reproduce these findings. 
38
  
These differences are confounded by the different techniques used by the various groups to determine 
in vivo HbSNO concentrations. 
 
1.6 Descriptors of Oxygen Levels 
 
In order to avoid misunderstandings that may arise from imprecise use of terminology it may be 
helpful to clarify basic terms at this point.  Hypoxia refers to reduced oxygen levels in tissues whereas 
hypoxaemia refers to reduced circulating arterial free oxygen levels.  Alternatively hypoxia could be 
defined as a failure of normal tissue oxygenation and hypoxaemia as a failure of normal 
blood oxygenation. 
By way of nomenclature normoxaemia is defined as a  pO2 in the range of 77mmHg to 100mmHg.
39
  
Free oxygen levels in excess of this range is defined as hyperoxaemia  and conversely levels below 
this range are classified as hypoxaemic. 
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At a tissue level oxygen levels vary from 15mmHg in perivenous tissue to just under 100mmHg in 
periarterial tissue. Mitochondrial respiration is severely compromised by oxygen levels below 
1.5mmHg and as such anoxia is defined as the range 0-1.5mmHg and hypoxia as 1.5 – 15mmHg.39 
 
1.7 Inorganic Nitrite ‘Rediscovery’, Historical perspective 
 
 
NOx species have been used for over a century in clinical medicine
40
.  While the enthusiasm of 
chemists such as Alfred Nobel led to the discovery of the destructive powers of TNT the same 
curiosity has led to the use of the substances in the treatment of myocardial ischaemia.  So successful 
was this discovery that patients continue to benefit from these anti-anginal properties to this very day. 
In 1844 amyl nitrite was synthesised by Antoine Balard and its effects subsequently studied by the 
English Chemist Fredrick Guthrie.  When inhaled it was noted that amyl nitrite produced facial 
flushing, throbbing of neck arteries and tachycardia
40
.  Based on these findings physicians used amyl 
nitrite successfully to treat angina pectoris prior to the development of glyceryltrinitrate (GTN).  GTN 
superseded organic nitrite primarily due to its longer duration of action. Nitrite was subsequently 
placed back on the chemist’s shelf and it has remained there until recent years.  Interest has however 
been reignited as the concept of ‘transported nitric oxide’ has developed. 
 
The role of inorganic nitrite in normal physiology, however, continues to be the subject of hot debate. 
Although it is well recognised as a relatively weak direct dilator of arteries in normoxia, the potential 
for circulating nitrite in plasma to act as a reservoir of vasoactive NO that can be released when 
tissues are stressed by ischaemia/ hypoxaemia continues to be investigated. 
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1.8 The “Nitrite Theory” 
 
This proposed model focuses on the nitrite anion as the main reservoir of ‘transported NO’.  For many 
years nitrite was considered to be a metabolic ‘dead end’ of NO oxidation since its vasodilatory 
properties were observed to be  modest at most
41
 or at best a metastable intermediate in the formation 
of nitrate from NO radicals, a cascade that was felt to be irreversible.    Lauer and colleagues 
infused sodium nitrite into the brachial arteries of healthy volunteers at physiological doses 
(0.01–36 µmol/min) and observed no changes in forearm blood flow (FBF), indicating a lack 
of vascular dilatation
42
. Most of the early work, however, was performed in vitro and in normoxic 
conditions
41
.  Interestingly in 1998 Furchgott noted in his Nobel lecture that under acidic conditions 
nitrite potently relaxed vascular rings.  More recently in vivo work has rekindled interest in the nitrite 
anion.  Studies by Gladwin and co-workers found that, in contrast to other NO metabolites, there are 
significant gradients of nitrite across the forearm vascular bed, particularly during exercise
43
.  Intra 
arterial nitrite retained its vasodilatory effect after inhibition of nitric oxide synthase (with L-NMMA) 
and forearm exercise, from which a physiological role for the nitrite anion was suggested
5
.  In contrast 
to the findings of Lauer and colleagues, more recent work has found nitrite to be capable of increasing 
forearm blood flow when infused into the brachial artery at physiologically relevant doses
44, 45
.  
Intrabrachial infusions of nitrite at concentrations as low as 0.07µg/kg/min, leading to a rise in plasma 
nitrite levels from 300nM to 350nM, have been reported to lead to a modest but significant  increase 
in Forearm Blood Flow in healthy human volunteers. 
46
 
 
 
 
 
 
 
29 
 
1.9 Nitrite Reduction 
A variety of different nitrite reductases have been identified. These include pH-dependent enzyme-
independent nitrite conversion to NO,
47
 deoxyhemoglobin,
48-54
 myoglobin,
55-59
 neuroglobin,
60
 
aldehyde oxidase,
61
 microsomal cytochrome P-450
62
,  cytochrome C
63, 64
, and mitochondrial aldehyde 
dehydrogenase
65
.  However the relative importance of these different mechanisms in vivo remains 
unclear. Since the different proposed reductases exhibit tissue specificity, synergy, redundancy and 
sensitivity to incipient conditions
66
; and since nitrite is reduced via  a number of mechanisms ex vivo, 
there are significant challenges to translating in vitro nitrite reducing capacity to in vivo physiology. 
For example, there has been controversy regarding the role of red blood cells (RBCs), hemoglobin 
(Hb) and deoxyhemoglobin in nitrite metabolism.
48-54, 67-69
 Although there is a clear chemical rationale 
for the Fe
II
 centre of Hb to reduce nitrite, the NO scavenging capacity of the plentiful heme groups in 
RBCs has led to  ongoing discussion regarding  their likely net NO yield.
61
  To reconcile this 
discordance, the membrane compartment hypothesis contends that RBC membrane eNOS and XOR 
generate NO at a distance from the RBC heme, hence the NO is free to diffuse to the vasculature. 
 
Similarly, building on existing evidence that the vasculature has intrinsic nitrite reductase activity,
70
 
and that XOR and eNOS have been implicated as nitrite reductases for several years;
58, 59, 61, 68, 70-72
, it 
has recently been  reported  that nitrite conversion to NO by the vasculature and/or by RBCs is 
attenuated by inhibition of xanthine oxido reductase (XOR) at very low oxygen tensions at pH 6.8. 
Furthermore, it has been shown that RBC endothelial nitric oxide synthase (eNOS) inhibition with L-
NMMA diminishes nitrite bioconversion.
73
  These proposals have merit as they reconcile the long 
held belief that RBCs yield NO with the concern that high RBC Hb concentrations would attenuate 
NO release through scavenging.  However, while these findings may be applicable to nitrite 
bioconversion in the context of pronounced pathological hypoxia, the implication of these 
observations to the vasodilation observed with pharmacological concentrations of nitrite under 
normoxic and mildly hypoxic conditions is unclear.  
30 
 
Zuckerbraun and co-workers. have recently reported that inhaled nitrite confers protection in a rodent 
model of pulmonary hypertension and that this protection appears to be dependent on XOR
74
.  
Recently, work by our Group investigating the role of XOR and NOS in nitrite bioconversion  during 
mild (physiological) hypoxia in healthy human volunteers has demonstrated that the role of these 
enzymes under these conditions appears to be minimal (chapter 4). 
 
1.10 Limitations of the Nitrite theory 
 
This model has been challenged by some.  Luchsinger and colleagues (2005) question the 
interpretation of many of the findings mentioned above, in particular the relative concentration of 
nitrite in the resistance versus the capacitance bed 
75
.  The arterio-venous nitrite gradients that have 
been observed are interpreted to reflect decreased NOS activity coupled with increased nitrite 
consumption rather than a gradient created by the delivery of NO by nitrite.  Moreover the authors 
argue that any vasodilatation that is observed with nitrite is effected via the formation of SNO-Hb 
which they contend is a much more potent vasodilator. 
Furthermore, deoxyhaemoglobin has been proposed as a nitrite reductase.  
76
  However, this model 
has been seen as problematic.  If nitrite is reduced in the red blood cells to NO then a mechanism 
needs to exist to enable NO to ‘escape’ since deoxyhaemoglobin will aggressively bind to any NO in 
its vicinity.  Both the “membrane compartment hypothesis” and the suggestion that an ‘intermediary 
molecule’ may be generated in the reduction of nitrite, have been proposed as theories that may 
reconcile this apparent discrepancy. It has been proposed that this intermediary may be N2O3. 
77
  
Under this proposal N2O3 may be formed via a series of reactions that are initiated by the reduction of 
nitrite to form methaemoglobin and NO.  The methaemoglobin thus formed reacts with nitrite to form 
Hb-NO2
-
. The Hb-NO2
-
 then reacts with NO to form Hb and N2O3. 
77
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1.11 Formation of Nitrite and the role of Caeruloplasmin 
 
The principal mechanism leading to nitrite generation was previously thought to be auto oxidation of 
NO
78
.  While this has been demonstrated to occur in vitro its relevance in the physiological setting is 
less clear.  The estimated half-life for this reaction (k = 2x10
6
M
-2
s
-1
) is over thirty minutes.
79
  In 
contrast the reaction of NO with haemoglobin to form nitrate is orders of  magnitude greater (k = 
3.4x10
7
M
-1
s
-1
)
80
 and would result in any auto-oxidation of NO to be completely overwhelmed leading 
to NO being converted almost exclusively to nitrate with little or no nitrite generation.  For this reason 
mechanisms underlying the generation of nitrite were investigated.  It was found that whereas plasma 
displays the ability to generate nitrite upon the addition of the NO donor Diethylamine nitric oxide 
(DEANO), phosphate buffered saline (PBS) did not, implying that an intrinsic component of plasma 
facilitates NO oxidation to nitrite.
81
  Furthermore it was found that this process was inhibited by 
reductants such as glutathione and ascorbate but not by oxidants or by the thiol alkylating agent N-
ethylmaleimide (NEM).  Ultrafiltration of the plasma to remove high molecular weight proteins 
similarly decreased nitrite production focussing attention on caeruloplasmin.  Removal of 
caeruloplasmin from plasma by immunoprecipitation decreased nitrite production to levels observed 
in PBS strongly suggesting a critical role for this enzyme in nitrite production.  This was given further 
weight by the observation that caeruloplasmin knockout mice exhibit significantly lower plasma 
nitrite levels than their wild type equivalents, 0.51± 0.05µM vs  and 0.79± 0.08µM  respectively and 
the response to the addition of an NO donor was significantly blunted.  These observations were 
mirrored in patients with acaerulaplaminaemia.  The important role played by caeruloplasmin was re-
emphasised by the finding that hepatic injury sustained during ischaemia-reperfusion was greater in 
knockout mice and that this was ameliorated by the exogenous administration of intraperitoneal 
nitrite
81
.   
 
 
32 
 
1.12 Diet and endogenous Plasma Nitrite levels 
 
Approximately 70% of plasma nitrite is formed intravascularly as a metabolite of NO generated from 
eNOS, the remainder being dietary in origin, 
82
 Spinach and Beets being particularly rich sources of 
nitrite (2.0 to 4.0mg/kg food) along with baked goods and cured meats.  Reduction to NO takes place 
in the acidic conditions of the stomach leading to the NO generated being absorbed into the 
bloodstream where it is then oxidised to Nitrite.
83
  
Plasma nitrite levels are also influenced by dietary nitrate intake.  While small quantities of nitrate are 
present in fish and dairy produce, larger quantities are present in vegetables e.g lettuce and beetroot.  
The inorganic nitrates are absorbed into the bloodstream and concentrated in the salivary glands.  
Interestingly commensal bacteria in the oral cavity (posterior crypts of the tongue) and intestine 
appear to play an important role in the generation of nitrite  due to the nitrate reductase properties of 
these organisms.  Plasma nitrite levels were noted to increase after an oral nitrate load with 
attenuation of this effect following the administration of a mouthwash beforehand.
84
 
Physical activity leads to increased arterio-venous gradients.  This fact combined with variations in 
the nitrite pool secondary to dietary factors and social factors (e.g.smoking)  leads to variance in 
measured plasma nitrite levels.  However plasma nitrite levels tend to fall within the 150nM to 500nM 
range. 
85
 Levels have been found to be significantly increased in individuals suffering an intercurrent 
infective illness. Asymptomatic  HIV patients were found to have normal levels of plasma nitrite 
(0.4µM) whereas those suffering an infective illness (Pneumonia/ CMV retinitis) had markedly raised 
levels (36.2µM). 
86
 
Similarly the physiological changes of pregnancy are associated with lower levels of circulating 
nitrite.
87
  Levels of 0.48µM were observed in pregnant women in the third trimester as compared to 
1.13µM in non pregnant women.  No significant difference was seen between pre-eclamptic and non 
pre-eclamptic women.   
Plasma nitrite concentrations are profoundly affected by physiological adaptations to altititude.
88
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The nitrite pool is composed of both a red blood cell (RBC) and a plasma component. RBCs 
contribute a larger fraction to this pool.  The concentration in RBC’s is approximately double that in 
plasma (121nM and 288nM in plasma and RBCs respectively). 
89
 
Both plasma and RBC Nitrite levels are significantly higher in some rodents as compared to man.  
Levels as high as 1.6µM have been reported in mouse plasma
90
 and 10µM in Sprague-Dawley rats
91
. 
 
1.13 Nitrite and “The Mediterranean diet” 
 
As mentioned above the dietary content of nitrite and nitrate contribute to plasma nitrite 
content.  It has been hypothesised that the benefits of the “Mediterranean diet” may be 
explained by greater levels of nitrite and nitrate intake. The amount of vegetables consumed 
on average in higher is the Mediterranean diet as compared to most European and Northern 
American diets.  In the UK the average daily vegetable consumption has been reported as 
160mg per day 
92
 whereas Trichopoulos reported average vegetable consumption of 550g per 
day in the Mediterranean diet; approximately three times higher.
93
  The greater nitrite/nitrate 
consumption that results from a greater vegetable intake (approximately 4-fold) has been 
suggested to contribute to the beneficial effects of the Mediterranean diet.  
The Mediterranean diet has been associated with reduced morbidity and mortality.  A recent 
meta-analysis suggested the Mediterranean diet was associated with a significant reduction of 
overall mortality [relative risk (RR) = 0.92], cardiovascular incidence or mortality (RR = 
0.90), cancer incidence or mortality (RR = 0.94), and neurodegenerative diseases (RR = 
0.87).
94, 95
  A number of studies have reported an advantageous effect of increased inorganic nitrate 
intake upon human blood pressure profile. 
95, 96
 With the background of these observations Raat and 
colleagues examined the effect of a nitrate/ nitrite deplete diet versus a diet leading to normal plasma 
nitrite levels upon liver ischaemia reperfusion injury in mice.
97
  Dietary nitrite depletion led to 
34 
 
significantly lower stomach content, plasma, liver and heart levels of nitrite. The severity of ischaemia 
reperfusion injury as assessed by liver infarct size was significantly greater in the animals receiving a 
nitrate/ nitrite deplete diet.   
An interesting study by Webb and colleagues investigated the acute effects of an inorganic  nitrate 
load (in the form of 500ml beetroot juice) upon blood pressure, endothelial function and platelet 
aggregation.  The nitrate load equated to 2.79g/L; nitrite levels were undetectable.  Ingestion of 500ml 
of water served as the control arm.   Subjects receiving beetroot juice demonstrated a significant 16 
fold increase in nitrate which remained elevated for almost 24 hours.  Plasma nitrite levels in the 
study arm doubled and remained significantly elevated for 5 hours.  There was no significant change 
in plasma nitrate or nitrite levels in the control group.  Beetroot juice ingestion was associated with a 
significant 10.4mmHg drop in systolic blood pressure and 8.1mmHg drop in diastolic blood pressure, 
interestingly without a significant increase in heart rate.  This drop in blood pressure was mirrored by 
an improvement in endothelial function (as measured by flow mediated dilatation) following I-R 
insult and an inhibition of platelet aggregation.  Interruption of entero-salivary circulation by spitting 
out saliva over the 24 hour study period resulted in an abolition of the rise of nitrite levels but no 
change in the rise in nitrate levels.  Spitting resulted in the eradication of the beneficial effects upon 
blood pressure and platelet function suggesting that the favourable effects of beetroot juice ingestion 
were nitrite rather than nitrate mediated.
98
  A more recent study by the same group found the results 
mentioned above were reproduced when Beetroot juice was replaced by an equivalent quantity of 
inorganic nitrate in the form of potassium nitrate.
99
  These results could potentially lead to 
improvements in public health through dietary interventions aimed at improving blood pressure 
control and hence cardiovascular fitness. 
 
1.14 Mitochondrial Efficiency 
 
A fascinating recent paper by Larsen and colleagues investigated the impact of oral sodium 
nitrate loading upon exercise capacity. 
100
  It has previously been reported that oral loading of 
35 
 
inorganic nitrate increases exercise capacity.  A randomised double blind placebo controlled 
trial investigating oxygen consumption during exercise, with and without an oral nitrate load 
was performed.  Healthy volunteers were randomised to receive oral sodium nitrate 
(0.1mmol/kg/day) or placebo (sodium chloride).  All subjects performed cycle ergometer 
exercise tests before and after treatment at increasing exercise intensities.  It was found that at 
equivalent exercise intensities, at the four lowest levels, the oxygen consumption (V02) was 
significantly lower in the nitrate treated group.  This was despite a similar heart rate, lactate 
[Hla], ventilation (VE), VE/Vo2 and respiratory exchange ratio.  These observations 
effectively re-wrote the received wisdom that oxygen consumption was fixed for a given 
workload and were the first to demonstrate an intervention that could modulate VO2 for a 
specified level of exercise.
101
   
A more recent study by the same group investigated this phenomenon further.
100
  
In a double blind cross-over trial Larsen and colleagues sought to ascertain the mechanisms 
underpinning this improved oxygen consumption efficiency.  14 healthy subjects were randomised to 
receive either oral sodium nitrate (0.1mmol/kg/day) or placebo (sodium chloride) for a total of 
three days prior to testing with a 6 day ‘washout’ prior to crossover.  At the end to each stage 
a muscle biopsy and submaximal cycle ergometer test was performed.  The mechanical work 
to oxygen uptake was significantly improved by 3% in the nitrate treated group, as previously 
described.  Analysis of the muscle biopsies revealed a higher respiratory control ratio in the 
mitochondria of the nitrate treated subjects, indicating better coupling between respiration 
and oxidative phosphorylation.  This increased oxidative phosphorylation efficiency suggests 
that a greater proportion of the membrane potential was dedicated to ATP synthesis and less 
was wasted as a result of uncoupling.  This phenomenon was appeared to be due a reduced 
expression of ATP/ADP translocase. The results of this study not only inform our 
understanding of exercise physiology but may also prove relevant to the protective effect of 
36 
 
nitrite in the ischaemia-reperfusion setting because this channel appears to be a constituent of 
the mitochondrial permeability transition pore, the opening of which is central to IRI 
102
.  
Further studies are clearly indicated. 
 
1.15 Dietary Nitrate/ Nitrite – Health concerns 
 
Public health concerns were voiced regarding dietary nitrate ingestion in  1945.
103
  Nitrates have long 
been used as plant fertilisers and anxieties have been expressed regarding the contamination of 
drinking water by such agents.  Children in Iowa, USA drinking reconstituted milk that had been 
prepared using water from rural wells were found be suffering from vomiting, cyanosis and failure to 
thrive.  Laboratory examination revealed evidence of methaemoglobinaemia which corrected when 
alternative water supplies were used.  This observation was attributed to a high nitrate content in the 
well water. Further studies have suggested that it was in fact the combination of high nitrate content 
and bacterial contamination that was causing harm.  It was argued that the bacterial contamination 
lead to reduction of nitrate to nitrite which then oxidised oxyhaemoglobin (ferric) to methaemoglobin 
(ferrous) in vivo. 
104
   
 
NO2
-
  + oxyHb(Fe
2+
)   → metHb(Fe3+ ) + NO3
-
 
 
 
However since the initial concerns legislation across the industrial world is in place to limit the nitrate 
content of drinking water. 
While fatal (sometimes deliberate) poisoning due to nitrite ingestion in adults has been reported 
105
 no 
cases of methaemogloinaemia have been reported in (non infant) children and adults secondary to 
elevated nitrate levels in drinking water.  There are a number of reasons for this.  Firstly, the pH of 
gastric contents is higher in infants (>4.0) resulting in less degrading of nitrite and hence more 
37 
 
absorption.  Secondly, the methaemoglobin reductase enzyme system does not mature until after 
weaning.  Thirdly, the intakes of food and water in infants is roughly three times that of adults relative 
to body weight.  Fourthly, the levels of reducing agents such as, ascorbic acid, secreted in the stomach 
of infants of much lower than that of adults.  
 
Magee and Barnes reported that preformed nitrosamines and nitrosamides are carcinogenic in 
animals.  Anxieties were expressed regarding the potential for ingested nitrates and salivary nitrites to 
nitrosate ingested amines to form potentially carcinogenic nitrosamines. 
Epidemiological studies do not correlate with these theoretical concerns since it has been reported that 
populations which consume  a high vegetable intake (and therefore high inorganic nitrate)  enjoy 
lower rates of malignancy.
106
 
Studies investigating the potential link between dietary nitrate and gastrointestinal malignancy have 
produced conflicting results.  Hill and colleagues found higher than average rates of death from 
gastric cancer in Worksop in 1973 prior to restrictions on the nitrate content of drinking water 
107
.  
The average weekly nitrate consumption was twice that of the national average (980mg vs 440mg).  
Interestingly although death rates from gastric cancer were significantly greater in this population 
when compared to towns with a similar socio-economic make up, rates of gastric cancer per se were 
not significantly elevated.  Moreover the authors report significantly increased rates of death from 
gastric cancer in Sutton-in-Ashfield where the dietary nitrate content was no higher than other 
‘control towns’.  This observation casts doubt on the assumption of a causative link between the 
increased death rates and dietary nitrate intake in Worksop.  More recent retrospective 
epidemiological studies have found no positive association between malignancy rates and nitrate 
intake.  Some even report and negative correlation.
108
  The case against a causative role is supported 
by the temporal separation between ingested amines and the formation of nitrite via the entero-
salivary circulation.  Moreover gastric pH rises during a meal leading to an environment that is hostile 
to the formation of nitrosamines.
109
  Gastric secretions contain ascorbic acid which promotes 
reduction of nitrite to NO and helps prevent any potential nitrosamine formation.
110
  The World 
38 
 
Health Organisation 
111
 and the American Cancer Society 
112
  have each concluded that there is no 
evidence for a link between inorganic nitrate consumption and increased risk of cancer. 
 
1.16 Non NO mediated Nitrite Effects 
 
Sodium Nitrite has an established use in the treatment of hydrogen sulphide and cyanide poisoning.  
The pharmacological doses of inorganic nitrite leads to the formation of abundant levels of 
methaemoglobin which acts as a scavenger, deactivating both hydrogen sulphide and cyanide.  
113
 
 
Nitrite infusion over 24 hrs has been shown to lead to alterations in the expression of heat 
shock proteins in a range of organs. These effects were not inhibited by NO scavengers.  
Oxy-Hb had no effect in vitro and C-PTIO had no effect in vivo.  As such it has been 
suggested that nitrite may act as a signalling molecule in its own right at normal 
physiological oxygen levels. 
 
1.17 Therapeutic Avenues 
 
There is currently great interest in the potential role of the nitrite anion in pathological states, 
particularly in the context of ischaemia-reperfusion in many organ systems
114
.  The role of nitrite in 
hypoxic signalling includes vasodilatation, cytoprotection following ischaemic attack and alteration of 
mitochondrial respiration, potentially through both NO and non-NO mediated pathways. 
 
Gonzalez and colleagues (2008) investigated the effect of administering intravenous nitrite 
systemically in a canine model of myocardial infarction.  An impressive 70% reduction in myocardial 
infarct size (as a percentage of the area at risk assessed by first pass myocardial perfusion magnetic 
resonance imaging) was observed in these animals.
115
  Furthermore the infusion of nitrite to achieve 
39 
 
plasma concentrations of between 5 - 10µmol/L tended to result in subendocardial infarcts as opposed 
to transmural infarcts in the control group.   
The cytoprotective properties of nitrite may be mediated via hypoxic NO release mediated by 
myoglobin resulting in inhibition of cytochrome oxidase C.
116
    
In vitro studies utilising horse heart homogenate observed that deoxymyoglobin acted as a potent 
nitrite reductase 36 times faster than deoxyhaemoglobin.  The NO generated from nitrite was shown 
to inhibit mitochondrial respiration in rat heart and liver isolates.
76
  NO has previously been shown to 
inhibit mitochondrial respiration by binding to cytochrome c oxidase particularly at lower oxygen 
concentrations. 
117
 
Infusion of nitrite containing perfusate into isolated pig lungs has been shown to lead to a decrease in 
pulmonary vascular resistance and an increase in exhaled NO. 
118
 
In support of an enhanced role for nitrite in hypoxia, in vitro nitrite administration has been shown to 
confer protection against ischemia/reperfusion injury in the kidney, brain and liver.
119-122
  Duranski 
and co-workers (2005) found that intraperitoneal injections of nitrite (48nmol) in a murine model of 
hepatic ischaemia reperfusion injury led to significantly lower rises in serum tranaminase levels 
despite a very modest rise in serum nitrite levels (594 to 727nM).  Similarly intraventricular 
administration of nitrite conferred protection after coronary artery occlusion and reperfusion.  48nmol 
of nitrite injected into the left ventricle resulted in an impressive 67% decrease in infarct size.  In 
these studies neither nitrate nor buffer conferred any protection to ischaemia reperfusion injury. 
123
 
In addition, nitrite treatment has also proved beneficial in models of hypertension 
124
 and pulmonary 
hypertension 
125
  
The potential benefits of nitrite are not however limited to the setting of acute ischaemia reperfusion 
injury.  Kumar and colleagues (2008) studied the effects of chronic nitrite injection (given and twice 
daily intraperitoneally)  in chronic hind limb ischaemia induced through common femoral artery 
ligation in mice.  Nitrite administration was found to result in a greater vascular density through 
angiogenesis and the formation of collaterals as well as endothelial cell proliferation.  Over a seven 
day period hind limb blood flow returned to close to normal with nitrite treatment but not without. 
40 
 
The NO scavenger carboxy PTIO abolished these effects suggesting that they are mediated through 
the generation of NO.
126
 
Nitrite may have a positive role to play in the treatment cerebrovascular accidents.  ‘Thread 
occlusion’ of the middle cerebral artery was employed to induce cerebral infarction in adult male rats 
127
.  Intravenous infusion of sodium nitrite at the time of reperfusion resulted in a significant reduction 
in cerebral infarct size measured using triphenol tetrazolium chloride (TTC) staining 24 hours after 
ischaemia reperfusion.  Infusion of 48nmol and 480nmol of nitrite produced a 33% and 77% 
reduction in infarct respectively.  Interestingly higher doses of nitrite (4800nmol) failed to achieve the 
same outcome.  Infusion of sodium nitrate (480nmol) failed to demonstrate any reduction in infarct 
magnitude.  The protective effects of nitrite infusion were abolished by pre treatment with Carboxy-
PTIO.  These results may translate into clinical benefit.  Neurological outcomes were assessed using 
Modified Limb Placing and Rotorod behavioural tests. Nitrite treated animals demonstrated a 25% 
improvement as compared to the saline treated group. 
Subarachnoid haemorrhage (SAH) often presents with catastrophic consequences in young patients.  
While the initial bleeding leads to significant cerebral damage, late vasospasm has been recognised as 
a serious life threatening c omplication.  This has traditionally been treated prophylactically with 
nimodipine.  Pluta and workers (2005) investigated the part that nitrite infusion may play in treating 
this complication 
128
.  SAH was induced in cynomolgus monkeys and angiographic evidence of 
delayed vasospasm was assessed.  Continuous intravenous infusion of sodium nitrite, with additional 
daily boluses, resulted in no observable angiographic spasm.  In contrast, animals treated with 
intravenous saline all displayed angiographic vasospasm with one of this control group dying as a 
consequence.
128
  
 
 
Chronic Heart Failure (CHF) is often complicated by Diastolic Ventricular Interaction (DVI) leading 
to left Ventricular (LV) filling being compromised despite high left ventricular diastolic pressure
129
.  
A volume overloaded Right Ventricle forces the septum to be pushed towards the LV and also leads 
41 
 
to a rise in pericardial pressure resulting in LV constraint.  In this situation, relief of this DVI leads to 
an improvement in cardiac output.  An ‘un-balanced’ vasodilator that preferentially dilates the venous 
capacitance bed more than the resistance bed could potentially achieve relief of DVI.  Organic nitrates 
remain an important and widespread form of treatment for patients with both acute and chronic heart 
failure. However, organic nitrates suffer from a number of major drawbacks in the treatment of 
decompensated heart failure. They markedly dilate resistance as well as capacitance vessels at higher 
concentrations, with the resulting hypotension often limiting dose escalation. Furthermore, resistance 
and the development of tolerance are significant clinical issues
130
. Intra-arterial nitrite infusion leads 
to a relatively selective venodilatation
131
  and therefore has the potential of being invaluable in the 
treatment of patients suffering with heart failure particularly during an acute decompensation. We 
have recently studied the vascular effects of nitrite in patients with chronic heart failure and found the 
‘venoselectivity’ to be preserved at higher doses although at lower doses the arterial response to nitrite 
in the patients group appears to be amplified possibly as a result of greater resting oxidative stress in 
these subjects (chapter 3). Furthermore, recent published data suggests that continuous treatment with 
nitrite may not induce tolerance
46
 seen with organic nitrate treatment. 
 
1.18 Future Directions 
 
A wealth of in vitro and in vivo animal data presented herein has demonstrated the potential role of 
nitrite as a potential reservoir of bioactive NO. This alongside the paucity of human data available has 
paved the way for human studies particularly in disease states, such as heart failure and ischaemic 
conditions.  The impressive reduction in myocardial infarct size demonstrated raises the possibility of 
nitrite being used as adjunctive therapy in conditions affected by ischaemia-reperfusion injury.  The 
resultant salvaging of critically ischaemic but viable tissue could lead to profound improvements in 
patient recovery. Patients with heart failure may benefit from a vasodilator with selective venodilatory 
properties and lack of tolerance. Further work needs to be undertaken in this area to fully elucidate the 
benefit of nitrite in human pathology. 
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1.19 The current studies presented in this thesis 
 
With this context in mind we designed a series of studies to investigate the role of inorganic nitrite in 
health and heart failure. 
Our aims were: 
1) To investigate the role of nitrite in hypoxic vasodilatation at physiological and 
pharmacological doses. 
2) To investigate the responses of the vasculature in both health and heart failure subjects. 
3) To examine the mechanisms that may subserve the conversion of nitrite to NO 
4) To study the effects of systemic infusion of sodium nitrite and to determine its safety prior to 
larger investigations. 
5) To investigate the role of myoglobin in mediating NO release and the persistent vasodilatation 
observed. (This aim developed during the study). 
 
Our first objective was to establish the effect, in man, of intra-arterial sodium nitrite infusion upon 
both the resistance and capacitance beds as models of high oxygen tension environments and low 
oxygen tension environments respectively. 
Secondly, in order to determine whether any difference between the two beds was due to hypoxia per 
se and not due to an intrinsic difference between arteries and veins, we proposed to render the arterial 
circulation hypoxaemic (by volunteers breathing 12% oxygen) and to compare the resistance bed 
response in hypoxia to that in normoxia. 
Thirdly, to establish the effects to intra brachial nitrite infusion upon both the resistance and 
capacitance beds of patients with stable chronic heart failure, comparing the responses with those of 
healthy controls. 
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Fourthly, to determine the role of Nitric Oxide Synthase and Xanthine Oxidase mediating the 
vasodilatation and venodilatation induced by an intrabrachial infusion of nitrite at rest, in man 
breathing room air. 
Fifthly, to establish the effects to intravenous nitrite infusion upon peripheral blood pressure, central 
aortic pressures, cardiac output, total peripheral resistance, cardiac index, heart rate variability and 
baroreceptor sensitivity in healthy volunteers at rest. 
Finally to determine, using murine vascular rings, to the role of vascular myoglobin in mediating 
nitrite induced vasodilatation and the persistent relaxation observed in these studies. We proposed to 
inhibit myoglobin using carbon monoxide and employ the use of myoglobin knockout mice (with and 
without myoglobin transfection) to establish its role. 
 
 
In the following chapter I will describe the first set of experiments that provided the basis for all 
subsequent studies. We aimed to establish the effect of inorganic nitrite upon the vasculature of 
healthy volunteers at rest in normoxia and hypoxia.  
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Chapter 2 
 
Hypoxic Modulation of exogenous nitrite induced vasodilation in man  
The data presented in this chapter has been published in the journal “Circulation”. The reference is as 
follows: 
 
 Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, 
Ashrafian H, Born GV, James PE, Frenneaux MP.  Hypoxic modulation of exogenous nitrite-
induced vasodilation in humans. Circulation. 2008 Feb 5;117 (5):670-7 
 
Data has also been presented at international meetings as follows: 
 Maher AR, Gunaruwan P, Abozguia K, Palin TP, James PE, and Frenneaux MP. Sodium Nitrite 
is a Potent Venodilator.  The 56
th
 Annual American College of Cardiology (ACC) scientific 
sessions, March 2007, New Orleans, USA 
 
 Maher AR, Gunaruwan P, Abozguia K, Palin , James P, Frenneaux MP.  Venoselectivity of 
Nitrite: Evidence favouring Hypoxic release of NO.  The Annual Scientific Conference of 
The British Cardiovascular Society (BCS) June 2007, Glasgow, UK 
 
Execution 
I performed all of the recruitment and organisation of the appointments involved in the study.  I 
performed assessment of forearm blood flow, radionuclide plethymography and radionuclide 
ventriculography studies in the University of Birmingham.  Biochemical analysis was performed by 
Dr Phil James and his team at the University of Cardiff, Wales. The in vitro work described in this 
chapter was performed by Alexandra Milsom, University of Cardiff, Wales.  
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Abstract 
Background: It had been proposed that under hypoxic conditions nitrite may release Nitric 
Oxide (NO) causing potent vasodilatation. We hypothesized that nitrite would have a greater 
dilator effect in capacitance than in resistance vessels due to lower oxygen tension, and that 
resistance vessel dilation should become more pronounced during hypoxemia. The effect of 
intra-arterial infusion of nitrite on Forearm Blood Flow (FBF) and on Forearm Venous 
Volumes (FVV) was assessed during normoxia and hypoxia. 
Methods and Results: 40 healthy volunteers were studied. Following baseline infusion of 
0.9% saline, sodium-nitrite was infused at incremental doses from 40nmol/min to 
7.84µmol/min. At each stage, FBF was measured using strain gauge plethysmography.  FVV 
was assessed by radionuclide plethysmography. Changes in FBF and FVV in the infused arm 
were corrected for those in the control arm.  The peak percentage venodilation during 
normoxia was 35.8%±3.4% (Mean±SEM)   at 7.84µmol/min (P<0.001) and similar during 
hypoxia. In normoxia, arterial blood flow, assessed by the FBF-ratio (FBFR), increased from 
1.04±0.09 (baseline) to 1.62±0.18 (nitrite) (P<0.05) vs 1.07 ± 0.09 (baseline) to 2.37 ± 0.15 
(nitrite) (P<0.005) during hypoxia.  This was recapitulated in vitro, in vascular rings. 
Conclusions: Nitrite is a potent venodilator in normoxia and hypoxia.  Arteries are modestly 
affected in normoxia but potently dilated in hypoxia, implying the important phenomenon of 
hypoxic augmentation of nitrite mediated vasodilation in vivo.  There are therapeutic 
implications for the use of nitrite as a selective arterial-vasodilator in ischemic territories, and 
as a potent venodilator in heart failure. 
 
Key words: Nitric oxide, nitrite, veins, hypoxia 
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2.1 Introduction 
 
Debate surrounds the relative importance of different endogenous NO species in mediating 
physiological vasodilatation.  These species include nitrite, S-nitrosothiols, N-nitrosamines, 
iron-nitrosyls, and nitrated lipid.
132
 Nitrite has traditionally been considered a weak 
vasodilator.  In aortic specimens concentrations of nitrite as high as 100-1000µM are 
typically required under normoxic conditions to induce relaxation.
132, 133
 The discrepancy 
between plasma nitrite levels in vivo and the levels required to elicit a biological effect in 
vitro coupled with a study demonstrating lack of vasodilator activity of 200 µM nitrite in the 
forearms of healthy volunteers, diminished interest in nitrite.
134
  Nitrite thus ceded to 
hemoglobin acting as an NO store, oxygen sensor and condition-sensitive NO donor, 
operating through release of the NO group from SNO-Hb. 
33
 
 
More recently nitrite has been recognized as a powerful signaling molecule and regulator of 
gene expression.
135, 136
  Whilst in normoxia nitrite is a relatively inefficacious vasodilator 
when acting directly, during hypoxia this may be enhanced.  NO released from nitrite as a 
result of an hypoxic environment may  play an important physiological role.
132
  
Arteriovenous gradients of nitrite in the human forearm have been observed; these gradients 
are enhanced during exercise and during regional NO synthase inhibition.
5, 44
 Thus it has 
been suggested that nitrite is consumed to liberate bioactive NO.
5, 44, 132
 A vasoactive role for 
nitrite at normal physiological concentrations is still disputed as the arteriovenous gradient in 
nitrite may result from decreased venous nitrite production through decreased NO synthase 
(NOS) activity coupled with increased venous nitrite consumption.
75
  
It has recently been proposed that deoxyhemoglobin is capable of acting as a nitrite 
reductase; hence hemoglobin would act as ‘oxygen sensor’ and would liberate NO from 
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nitrite along the physiological oxygen gradient. The work of Gladwin and others is at least 
hypothesis generating with respect to a role for nitrite in the modulation of vascular tone in 
vivo.
132
  
In support of an enhanced role for nitrite in hypoxia, in vitro nitrite administration has been 
shown to confer protection against ischemia/reperfusion injury in the heart, kidney, brain and 
liver.
119-122
  In addition, nitrite treatment has also proved beneficial in models of hypertension 
124
, pulmonary hypertension 
125
 and cerebral vasospasm .
137
 
 
Accordingly, it was hypothesized:  (1) While breathing room air, nitrite would be a potent 
dilator of capacitance vessels in vivo because of their relatively low ambient oxygen tension; 
(2) On breathing 12% oxygen and rendering the resistance vessels relatively hypoxic, nitrite 
would become a potent arteriolar-dilator. 
  
This chapter focuses on the forearm vascular bed specifically assessing the resistance 
vasculature and the capacitance vasculature  (composed principally of the small veins and 
venules  which behave quite differently from conduit veins such as dorsal hand veins.) 
138
 To 
test the direct effect of nitrite on vascular tissue (haemoglobin-independent), isolated rabbit 
vessels (aorta and vena cava) were exposed to a range of nitrite concentrations in both 
normoxia and hypoxia.  
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2.2 Methods 
2.2.1 Subjects 
Twenty six healthy volunteers were recruited to Protocol A and fourteen to Protocol B.  
Subjects had no history of active smoking, hypertension, diabetes, hypercholesterolemia or 
family history of ischemic heart disease. None took cardioactive medication or vitamin 
supplements. All had a normal cardiovascular examination, electrocardiogram and gave 
written informed consent. The study was approved by the Local Research Ethics Committee. 
Investigations were performed at the University of Birmingham Clinical Research Block in a 
dedicated vascular laboratory (22 to 24°C) with subjects having had a light breakfast and 
abstained from caffeine-containing drinks for at least 6hrs.  
 
 
 
2.2.2 Measurement of Venous Volume 
FVV was assessed using radionuclide plethysmography. The details and advantages of the 
technique have been described.
139
  Briefly, after the administration of Stannous Fluoride 
venous blood was withdrawn, radio-labeled with Technetium99m and then re-injected into 
the subject after ten minutes incubation. After fifteen minutes for stabilization images were 
obtained.  A region of interest was defined and images were obtained during 1-minute 
acquisition periods. At least 90% of the injected isotope is confined to the intravascular 
space; therefore forearm radioactive counts are proportional to forearm blood volume. Since 
the vast majority of blood in the peripheral circulation is contained within the veins, changes 
in counts reflect changes in FVV.
139
 During each cycle of acquisition cuffs were inflated over 
both upper-arms at pressures of 0, 10, 20 and 30mmHg. From this data scintigraphic vascular 
volumes were plotted against cuff
 
pressure to form venous Pressure Volume Relationship 
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(PVR).  A parallel shift of the relationship indicated a change in venous tone.
139
 Data were 
acquired from both the study and control arm and any changes observed were corrected for 
those occurring in the control arm. This technique has been validated by a number of 
groups.
139-141
  Importantly, it has been shown that the position of the PVR is not altered by 
large changes in arterial inflow.
138
 To allow presentation
 
of grouped data, results were 
presented as percentages. The data were corrected for physical decay of technetium. 
 
  
Example of image from which scintigraphic vascular volumes were potted.  
 
 
Parallel shifts of the 
volume – pressure 
relationships represent 
changes in tone. 
Pressure
V
o
l
u
m
e
Change 
in Tone
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2.2.3 Biochemistry 
Chemicals and reagents 
Chemicals were purchased from Sigma other than glacial acetic acid, HPLC grade nitrite free 
water and hydrochloric acid which were purchased from Fisher Scientific.  
Sodium nitrite in the human studies was purchased from Martindale Pharmaceuticals, UK. 
 
Ozone-based chemiluminescence 
Plasma nitrite and protein-bound NO were measured using a tri-iodide reagent linked to 
ozone based chemiluminescence as described previously.
142
  The tri-iodide reagent is 
probably the most widely used in the NO metabolite field and has been validated against 
standards in several laboratories.
5, 143-146
  The reader is referred to a complete discussion of 
the assay.
33, 45, 142, 147-151
   
 
Stock solution of tri-iodide reagent was prepared fresh each day.
142, 146
  Immediately prior to 
analysis frozen plasma samples were thawed in a water bath at 37°C for 3 minutes.  We have 
previously shown sample freezing has no effect on plasma NO metabolite stability.
152
  Area 
under curve was used in analysis and concentrations were calculated from a standard curve of 
sodium nitrite. 
 
2.2.4 Study Protocols 
Protocol A (Normoxia) 
Subjects were rested supine.  Both forearms were positioned on the face of a gamma camera 
(Scintron, MIA and ADAC-Transcam).  A 20-gauge venous cannula was inserted into an 
ante-cubital vein in each arm.  Blood was drawn and sent for a Full Blood Count and 
Biochemical Profile. A 27-gauge arterial needle (Coopers Engineering, United Kingdom) 
51 
 
mounted onto a 16-gauge epidural catheter and sealed with dental wax was then inserted into 
the non-dominant brachial artery under sterile conditions and kept patent by the continuous 
infusion of normal-saline. 
 
 Example of subject during a study. 
 
Heart rate and rhythm were monitored continuously (Dash 3000, Marquette, GE). Blood 
pressure was monitored continuously with finger plethysmography (TNO TPD Biomedical 
Instrumentation, Delft, Netherlands).  Mercury in silastic strain gauges were used for the 
measurement of FBF (D.E. Hokanson, Inc., Bellevue, Washington), as described in the 
published literature.
153
  Changes in FBF observed in the study arm were corrected for those 
occurring in the control arm and expressed as a ratio (FBFR) (infused:control). Two venous 
PVR were recorded and FBF was assessed during the infusion of normal-saline. Blood was 
drawn from both venous cannulae (infusion and control arm) at baseline and at each stage of 
the study. Blood samples were transferred after blood gas analysis (Bayer Rapidlab 865) into 
4ml EDTA collection tubes and were centrifuged at 2000rpm for 10 minutes at 4
0
C.  Plasma 
was snap frozen in liquid nitrogen and stored at -80ºC for subsequent analysis.  Plasma nitrite 
and protein-bound NO were measured at each stage in both protocols. 
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Intra-brachial nitrite was then commenced at a dose of 40nmol/min for thirty minutes.  FVV 
was assessed at 5, 12 and 20 minutes followed by the assessment of FBF.  The above was 
then repeated with doses of nitrite of 100nmol/min, 314 nmol/min , 784 nmol/min, 
3.14µmol/min and 7.84µmol/min. Left ventricular ejection fraction was calculated by 
Multiple Gated Acquisition. In a subset of subjects (N=3) radial arterial samples were taken 
at baseline and at peak nitrite infusion in which levels of nitrite and protein-bound NO were 
measured.  
 
 
Example of FBF determination using strain gauge plethysmography. 
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Protocol  A 
 
  
 
Place subject on bed, ensure comfort, place 
venous cannulae and arterial access. Radio-
label  RBCs 
Infuse 0.9% Saline intra arterially. Determine 
FBF and UVV after 15 minutes. 
Infuse sodium nitrite at dose 1 determining FBF 
and UVV at 5, 12 and 20 minutes.  Withdraw 
venous blood for subsequent analysis. 
Repeat at doses 2,3,4,5 and 6. 
Perform MUGA 
Finish 
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Protocol B (Hypoxia) 
Subjects were prepared as for protocol A.  Oxygen saturation levels were monitored 
continuously using pulse oximetry (Nellcor N-180). Baseline measurements of all parameters 
were taken during the initial saline infusion.   
Hypoxia was induced with the subject breathing 12% oxygen via a facemask connected to a 
two way valve.  When arterial oxygen saturation levels (as measured by pulse oximetry) were 
stable in the range 83-88% [estimated p02 = 47.5-55mmHg, based on Severinghaus’ 
equation], FVV and FBF were assessed during saline infusion (‘hypoxia alone’) prior to the 
infusion of nitrite.   
 
In seven subjects intra-brachial nitrite was infused at a dose of 7.84µmol/min for 20 minutes 
in either normoxia or hypoxia, in random order. Saline was infused between the two infusions 
of nitrite for 60 minutes.  FVV was assessed at ten minutes into each nitrite infusion followed 
by the assessment of FBF. 
 
In the remaining seven subjects protocol B was performed using nitrite at a dose of 
314nmol/min in order to investigate the effects of hypoxia in the context of a plasma 
concentration of nitrite close to that found physiologically. 
55 
 
Protocol  B 
 
  
 
Place subject on bed, ensure comfort, place 
venous cannulae and arterial access. Radio-
label  RBCs 
Infuse 0.9% Saline intra arterially. Determine 
FBF and UVV after 15 minutes. 
Apply 12% Oxygen, ensuring subject well 
being and aim for oxygen saturation levels of 
83-88%. Determine FBF and UVV after 10 
minutes. 
 
Infuse sodium nitrite determining FBF and 
UVV at 20 minutes.  Withdraw venous blood 
for subsequent analysis. 
 
Remove 12% oxygen allowing subject to breath 
room air and infuse saline for 60 minutes. 
Infuse sodium nitrite determining FBF and 
UVV at 20 minutes.  Withdraw venous blood 
for subsequent analysis. 
 
Perform MUGA 
Finish 
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2.2.5 Vascular Tissue Assay 
These studies were perfomed by Dr Alex Milsom, School of Medicine, Cardiff University, 
Cardiff, United Kingdom 
Male New Zealand white rabbits (2 to 2.5Kg) were terminally anaesthetized by intravenous 
injection of sodium pentobarbitone (0.75ml/Kg). Abdominal aorta and vena cava were 
excised and placed in fresh Krebs buffer (NaCl 109.0mM, KCl 2.7mM, KH2PO4 1.2mM, 
MgSO4.7H2O 1.2mM, NaHCO3 25.0mM, C6H12O6 11.0mM, CaCl2.2H2O 1.5mM).  Vessels 
were cleaned and cut into 2mm rings. Rings were mounted on matched stainless steel hooks 
for isometric tension recording in 8ml baths containing 5ml of Krebs’s buffer.  
 
Tissue was allowed to equilibrate for 60 min under a resting tension of 2g at 37
0
C, the buffer 
being exchanged every 15 min. After final adjustment of the passive tension to 2g, vascular 
segments were constricted with phenylephrine (PE, 1µM). Once tension had reached a 
plateau, acetylcholine (10 µM) was added to demonstrate endothelium viability.  
 
Following extensive washout, under normoxic conditions (95% O2/5% CO2) vessels were 
again constricted with 1µM PE, and sodium nitrite in Krebs’s buffer (10M, 100M, and 
1000M final concentration) was administered. Under hypoxic conditions (95% N2/5% CO2 
resulting in 1% tissue bath O2) the tissue was first incubated for 10 minutes before exposure 
to 3µM PE (to achieve a similar gram tension observed at 95% O2) before administration of 
sodium nitrite. Tension was recorded for a further 20 minutes using ‘Chart for Windows’ 
(AD Instruments). Minimum tension achieved was used in all calculations. All relaxations are 
presented as a % of the maximum tension induced by PE under the relevant conditions.  
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2.2.6 Data and Statistical Analysis 
All data are expressed as mean ± SEM, and P values of <0.05 were considered statistically 
significant. Repeated measures analyses were carried out for changes in FBFR and FVV.  In 
vitro data was analyzed using two-way ANOVA. 
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2.3 Results 
Subject characteristics  
Table 2.1: Grouped baseline characteristics for all subjects. Continuous data are presented as 
mean±SEM. 
Demographic and Clinical Features 
 
Age (y)  
Sex, M/F 
Body mass index (kg/m
2
)  
Smoking history, (n) 
       Nonsmoker  
       Previous smoker  
       Current smoker  
Serum cholesterol (mmol/L)  
Plasma glucose (mmol/L)  
Serum Creatinine (µmol/l) 
Heart rate 
Blood pressure (mmHg) 
        Systolic 
        Diastolic 
Left Ventricular Ejection Fraction  
56.5±1.4 
27/6 
27.0±0.6 
 
32 
1 
0 
5.6±0.2 
4.8±0.1 
99.6±3.1 
64.0±2.0 
 
129±2.2 
73.1±1.7 
58.3±2.7 
 
 
2.3.1 Protocol A: Normoxia 
Venous Tone 
At doses of nitrite 784nmol/min, 3.14µmol/min and 7.84µmol/min very large decreases in 
forearm venous tone were observed (Figure 1).  The time course over which the dilatation 
occurred is presented in Table 2 and Figure 2.  The peak venodilation(%) at 3.14µmol/min 
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and 7.84µmol/min was (mean ± SEM) 20.6± 4.2 (P<0.05) and 35.8± 7.5 (P<0.005) 
respectively. 
 
Figure 2.1:  Change in peak forearm vascular volume under normoxic conditions. Data 
expressed as percentage change from baseline (saline infusion). All values are presented as 
mean±SEM, where * = P<0.05, and *** = P<0.001 compared with saline infusion. 
 
Dose of Nitrite % venodilation 
5 minutes 
% venodilation 
12 minutes 
% venodilation 
20 minutes 
40nmol/min 
100nmol/min 
314nmol/min 
784nmol/min 
3.14µmol/min 
7.84µmol/min 
-2.2 ± 1.7 
-5.1 ± 2.6 
1.6 ± 3.1 
4.0 ± 2.5 
17.6 ± 4.1 
29.1 ± 10.1** 
-2.8 ± 2.7 
-3.1 ± 2.3 
8.2 ± 4.0 
7.3 ± 2.7 
19.1 ± 3.3* 
30.7 ± 4.3*** 
-4.2± 1.5 
-0.8± 4.6 
8.1± 4.3 
10.3± 2.8 
20.6± 4.2* 
35.8± 7.5*** 
 
Table 2.2.  Venodilation at doses of sodium nitrite at 5, 12 and 20 minutes of infusion. All 
values are presented as mean±SEM, where * = P<0.05, ** = P<0.005 and *** = P<0.001 
compared with baseline. 
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Figure 2. 2:  Venodilation measured at 5, 12 and 20 minutes during infusion of nitrite at each 
of the infusion doses during normoxia. 
 
 
Arterial Blood Flow 
Only at 3.14µmol/min and at 7.84µmol/min were there noticeable increases in FBFR (Figure 
2.3).  At baseline the FBFR was 1.0 ± 0.1 (mean ± SEM).  At 3.14µmol/min and 
7.84µmol/min the FBFR (mean ± SEM) was 1.8 ± 0.3 and 1.6 ± 0.2 respectively (P<0.05). 
 
40 nmol/min 
100nmol/min 
314nmol/min 
784nmol/min 
3.14micromol/min 
7.84micromol/min 
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Figure 2.3: Forearm blood flow at incremental doses of sodium nitrite under normoxic 
conditions. Data expressed as a ratio of infused:control arm (FBF-R) to correct for any 
systemic changes, values are mean±SEM, where * = P<0.05, 
 
Plasma Nitrite and Protein-bound NO levels 
Venous plasma nitrite levels were significantly greater in the infused versus control arm at 
doses of 314nmol/ml upwards (P<0.05) (Figure 2.4) 
 
There was no statistically significant difference the venous levels of plasma protein-bound 
NO between the two arms at any dose (Figure 2.4). 
* * 
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Figure 2.4: Plasma nitrite (A) and protein-bound NO (B) levels under normoxic conditions. 
All values are presented as mean±SEM, where *** = P<0.001 compared with control arm. 
 
Arterial levels of plasma nitrite in the infused arm increased from 233nM ± 27.0nM at 
baseline to 34.1µM ± 12.3 µM (Figure 5A) (P<0.05). Arterial levels of plasma protein-bound 
NO in the infused arm increased from 64.0nM ± 5.8nM at baseline to 83.8nM ± 23.8nM 
(Figure 5B) (P=NS). 
Saline      314nmol    784nmol    3.14µmol    7.84µmol 
Saline      314nmol    784nmol    3.14µmol    7.84µmol 
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Figure 2.5. Arterial levels of plasma nitrite (A) and protein-bound NO (B) in the infused arm 
under normoxic conditions. Values presented as mean±SEM, where * = P<0.05, 
 
 
2.3.2 Protocol B: Hypoxia 
Venous Tone and Forearm Blood Flow 
 
The degree of venodilation in response to nitrite infusion was similar in patients breathing 
room air to those breathing 12% oxygen. However hypoxia significantly enhanced the 
increase in FBFR during nitrite infusion. The mean increase in FBFR during high dose nitrite 
infusion (7.84micromol/min) in hypoxia was significantly greater than that in normoxia 
(P<0.05) (Figure 2.6).  Low dose nitrite (314nmol/min) had little effect during normoxia but 
increased FBFR during hypoxia (P<0.05) (Figure 2.7). 
 
Saline   7.84µmol/min Saline   7.84µmol/min 
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Figure 2.6: The effect of hypoxia on the venodilatation (A) and FBF-R (B) induced by 
intrabrachial nitrite (7.84µM/min). Values presented as mean±SEM, where * = P<0.05 
compared with baseline and # = P<0.05 compared with normoxia and nitrite. 
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Figure 2.7:  The effect of hypoxia on the venodilatation (A) and FBF-R (B) induced by 
intrabrachial nitrite (314nM/min). Values presented as mean±SEM, where * = P<0.05 
compared with normoxia and nitrite. 
 
 
 
2.3.3 In vitro Work 
 
Nitrite-induced vessel relaxation increased proportionally with increasing nitrite 
concentrations in both aorta and vena cava (P<0.05) (Figure 2.8). No statistical difference 
was observed between the degree of nitrite-induced relaxation in the aorta versus vena cava 
under normoxia. 
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Hypoxia enhanced nitrite-induced relaxation in both vessel types when compared with 
relaxation under normoxia, however veins had a proportionally greater relaxation when 
compared with arteries at 100 and 1000µM nitrite (P<0.01). 
 
 
 
Figure 2.8: Relaxation of aorta and inferior vena cava following 20 minutes incubation with 
varying nitrite concentrations, under either normoxic or hypoxic conditions. Data presented 
as mean±SEM, each data set is n = 4-5. * =  P<0.05 hypoxia vs normoxia. 
 
* 
* 
* 
* 
* 
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2.4 Discussion 
 
This study showed that under normoxic conditions exogenous nitrite-induced vasodilation in 
humans occurred predominantly in capacitance vessels. Under these conditions nitrite only 
modestly increased FBF (x1.6) even at maximal arterial nitrite concentrations (~30 µM). 
Although hypoxia had no incremental influence on the effects of nitrite on capacitance 
vessels, at similar concentrations (~55 µM) it had a profound relaxing effect on resistance 
vessels.  The in vitro studies confirmed this influence of hypoxia on the nitrite-induced 
relaxation in both arteries and veins suggesting that oxygen tension is a major determinant of 
the degree of response to nitrite. 
 
Until recently the nitrite-anion was regarded as a relatively inert by product of NO 
metabolism and even as a potentially carcinogenic source of N-nitroso compounds.
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Recently, research has shown nitrite to be a distinct and important signalling molecule
136
  
Normoxic studies with animal aortic strips appeared to preclude a physiological role,
133
 but in 
contradistinction a physiological function for nitrite has been supported by the capacity of 
physiological nitrite concentrations (~1-2 µM) to dilate human resistance vessels.
44
  
 
We have now shown that exogenous nitrite is a potent dilator of the venous capacitance bed 
in humans, under both normoxic and hypoxic conditions. At peak dose we observed a ~40% 
venodilation; this is a large effect. Since up to 70% of the circulating blood volume resides 
within the capacitance bed, even subtle modifications of venous tone can result in large 
changes in central blood volume and cardiac ‘preload’. Accordingly, a strong selective 
venodilator may confer distinct benefits in the treatment of heart failure.  We have previously 
used carbachol extensively in studies assessing venous capacitance.
155
  At peak dose a 
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maximal 3-4 fold increase in forearm blood flow and a 40% venodilation was observed 
138
.  
Thus nitrite exerts similar venodilatory effects to carbachol with comparatively modest 
effects on resistance vessels during normoxia.   
 
The enhanced resistance vessel response to nitrite during hypoxia is consistent with the 
findings of Cosby et al who observed that the vasodilatory effects of intra-arterial nitrite were 
enhanced by the tissue hypoxia induced by exercise of the forearm.
44
  Moreover our study 
answers many of the questions that were raised following this publication and in particular 
demonstrates that hypoxia per se is a primary determinant in the action of nitrite.  We found 
that in normoxia low dose nitrite (314nmol/min) had no discernable effect on FBF, whereas 
Cosby et al observed a 29% increase in FBF in response to nitrite infused at 400nmol/min in 
normoxia, but Lauer et al reported that exogenous nitrite had no effect at all on FBF even at 
doses as high as 36 micromol/min.
134
  The reasons for this discrepancy may pertain to the 
differences in the subjects and the experimental protocols although such differences are not 
obvious as the preparation of nitrite and its infusion were similar.  It is unlikely that our 
subjects differed significantly in sympathetic stimulation
156
  It is however possible that there 
is heterogeneity in the handling of nitrite.  In our own study we found a significant degree of 
variation in the responses observed.  While in the majority of individuals nitrite doses as low 
as 314nmol/min had little measurable effect on FBFR, in a few subjects the effect was more 
pronounced.  In one individual the FBFR increased by 27%.  Such heterogeneity may explain 
some of the apparently contradictory findings in the literature and provides an interesting 
avenue for future work. 
 
While in normoxia nitrite was a weak vasodilator of resistance vessels when compared with 
agents such as acetylcholine
157
 and bradykinin
158
 that can induce a 3-4 fold increase in FBF, 
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in hypoxia we show that it becomes an arterial vasodilator of comparable potency to these 
agents.  Importantly, a significant augmentation in FBFR during hypoxia was also seen with 
low dose (314nmol/min) nitrite implying a possible physiological role under hypoxic 
conditions.  
 
Our vascular ring studies confirmed that, (in the absence of haemoglobin), nitrite-induced 
dilatation of veins and arteries is more profound in the context of hypoxia than in normoxia 
confirming the findings in vivo.  In vitro during hypoxia relaxation of veins was greater than 
that of arteries.  However it is not valid to directly compare potency between arteries and 
veins and extrapolate to the in vivo situation because of the unphysiological nature of the 
preparation which measures relaxation from a preconstricted state rather than changes in 
basal tone. 
 
Although this study confirms a role for hypoxia in facilitating exogenous nitrite-induced 
vasodilation, no conclusion can be drawn about the mechanisms subserving this effect. Both 
non-enzymatic chemical reactions
159
 and nitrite reductase species 
160
 as diverse as 
hemoglobin,
44, 45, 161
 xanthine oxidase, 
122
 endothelial NOS 
162
 and the mitochondrial enzymes 
cytochrome c oxidase and the bc1 complex 
163
 reduce nitrite hypoxically in vitro.  However 
their relative contribution to the hypoxic vasodilatatory response in vivo remains 
unresolved.
75, 132, 160
  In subjects infused with nitrite, NO adducts of hemoglobin are increased 
and it is suggested that hemoglobin is a key nitrite reductase.
44
 Hemoglobin can subserve a 
number of roles, including nitrite reductase in hypoxia; as an acceptor of the resulting NO 
(e.g. through HbNO); and as donor of NO precisely where it is required i.e. at the site of 
hypoxia (through HbSNO). These multiple personalities make hemoglobin an attractive 
nitrite modulator.  A recent in vitro study has observed that nitrite-dependant vasodilation 
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conforms to first-order reaction kinetics with respect to nitrite concentration. Using selective 
inhibitors during hypoxia, this study indicated that nitrite-induced vasorelaxation was 
independent of nitrite reductases listed above and importantly was inhibited by oxygenated 
haemoglobin but not by deoxygenated hemoglobin.
164
 This study did not exclude a role for 
haemoglobin as a nitrite modulator in vivo.  If nitrite is subject to hemoglobin-mediated NO 
production, how the resulting products or NO itself escape from the red blood cell is not yet 
clear as such an escape is difficult to reconcile with the diffusional limitations and the time 
constraints of an extremely quick A to V transit time.
75
  
 
 
To reconcile nitrite’s site and mechanism of action in vivo, vascular preparations will need to 
be further investigated. Specific agents and inhibitors are required to identify putative nitrite 
reductases, e.g. haemoglobin, myoglobin, neuroglobin and other heme proteins such as 
hypoxia-dependent nitrite reductases.
165
 The species to which nitrite is converted and which 
activates guanylate cyclase e.g. NO, iron-nitrosyl, N-nitroso and S-nitroso complexes will 
also need to be identified. Parallel in vivo studies will supplement the in vitro studies.  In the 
present study the venous plasma nitrosothiol levels rose similarly in both arms suggesting 
that protein-bound NO, in the plasma compartment, did not directly mediate the venous 
dilatation. This however does not preclude protein-bound NO within the red blood cells or 
within the vascular compartment contributing to the bioactive effects of nitrite. 
 
2.5 Limitations 
First, our study was performed in healthy volunteers and the response to nitrite may differ in 
disease. Second, organ chamber bioassays are limited by the complicating factor of varying 
baseline tension in pre-contracted vessels.
75
 As different vessels (capacitance vs resistance) 
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show different and non-linear responses, such bioassay results should be assessed judiciously 
and any interpretation of apparent differences between vessel types should be guarded. 
Nonetheless, our in vivo and in vitro studies are internally consistent. Third, our results 
increase the understanding of the synergy between nitrite and hypoxia but provide limited 
insights into the role of endogenous nitrites in physiology. We speculate that this study may 
also implicate a role for endogenous nitrites in hypoxic vessels, but we have limited any 
discussion of the role of nitrite in physiological hypoxic vasodilatation.
75
  Even in in vitro 
assays where unphysiologically high concentrations of nitrite (100µM) have previously been 
required, careful attention to pre-contraction and incipient conditions reveals that 
physiological concentrations of nitrite (0.1-10µM) can modulate tone.
164
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2.6 Conclusion 
This study confirms that hypoxia per se is a prime determinant of the in vivo response to 
exogenous nitrite. Both capacitance and resistance vessels respond profoundly to relatively 
modest pharmacological concentrations of exogenous nitrite in hypoxia. While for some 
years, based on studies in normoxic and exercising patients, it has been speculated that 
“therapeutic application of nitrite should result in selective vasodilation to hypoxemic tissue, 
and could be used to treat diseases associated with ischemia,”44 this study confirms the role 
for nitrite in resistance vessel dilatation in human hypoxic tissues. There are corresponding 
therapeutic implications; in conditions such as heart failure where selective venodilation 
would reduce intra-cardiac pressure in the absence of resistance vessel dilatation avoiding 
hypotension. Perhaps more importantly, pharmacological doses of nitrite may constitute a 
specific hypoxically bioactive agent that targets only hypoxic vessels.
119, 166, 167
 A preliminary 
indication of the importance of nitrite has been afforded by data presented by Arai et al, who 
demonstrated that a brief nitrite infusion (plasma concentration of ~5 µM) decreased 
myocardial infarction size from 70% to 20%.
132
 As well as confirming our findings, future 
studies will have to assess the therapeutic role of nitrite in disease. 
 
 
In the following chapter we built on the findings in chapter 2 and went on to investigate the 
vascular responses of chronic heart failure patients to intra-arterial nitrite infusion. 
A similar experimental set up was performed in order to compare the responses of these 
patients to those of healthy controls. 
 
 
73 
 
Chapter 3 
 
Impact of chronic congestive heart failure on pharmacokinetics and 
vasomotor effects of infused nitrite  
 
 
 
The data presented in this chapter is currently being considered for publication in the journal 
“British Journal of Pharmacology”.  
 
 
 
 
 
Execution 
I performed all of the recruitment and organisation of the appointments involved in the study.  I 
performed assessment of forearm blood flow, radionuclide plethymography and radionuclide 
ventriculography studies in the University of Birmingham.  Biochemical analysis was performed by 
Dr Phil James and his team at the University of Cardiff, Wales. 
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Abstract: 
Aims: Nitrite (NO2
-
) has recently been shown to represent a potential source of nitric-oxide 
(NO), with bio-activation of NO2
-
 to generate NO being potentiated in the presence of 
hypoxia. We now compared the acute hemodynamic effects of infused nitrite (0.31 to 
7.8µmoles/min) in normal subjects (n=20) and patients with stable congestive heart failure 
(CHF: n=21).  
Methods and Results:  NO2
-
 infusion was well tolerated in all subjects. Forearm blood 
flow(FBF) increased markedly in CHF-patients at NO2
-
 infusion rates which induced no 
changes in normal subjects (ANOVA: F=5.5; P=0.02).Unstressed venous volume (UVV) 
increased even with the lowest NO2
-
 infusion rate in all subjects, with CHF patients being 
relatively hyporesponsive compared with normal subjects (ANOVA: F=6.2; P=0.01).There 
were no differences in venous blood pH or O2 concentrations between groups or during NO2
-
 
infusion. Plasma NO2
-
 concentrations were lower in CHF-patients at baseline, and rose 
substantially less with NO2
-
 infusion, without incremental oxidative generation of nitrate, 
consistent with accelerated clearance in these patients. Plasma protein-bound NO 
concentrations were lower in CHF-patients than normal subjects at baseline.  This difference 
was attenuated during NO2
-
   infusion. 
Conclusions:  The findings  of arterial hyper-responsiveness to infused NO2
-
 in CHF-
patients, with  evidence of accelerated transvascular  NO2
-
  clearance (presumably with 
concomitant NO release) suggest  that NO2
-
 effects may be accentuated in such patients, 
despite the similar venous oxygen saturations and pH in patients and controls. Despite the 
finding of apparent tissue resistance to NO, as previously documented in CHF, these findings 
provide a stimulus for the clinical exploration of NO2
-
 as a therapeutic modality in CHF. 
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3.1 Introduction 
Although the mechanism(s) of bioactivation remain incompletely understood, a number of 
reductases have been shown to “reactivate” NO from NO2
-
, independent of endothelial nitric 
oxide synthase (eNOS) activity
168, 169
 . In the majority of studies, this process appears to be 
markedly potentiated in the presence of hypoxia, although once again it is not clear what 
mechanism(s) underlie this potentiation
131
. The implication of hypoxic potentiation of nitrite 
induced vascular relaxation is that exogenous administration of NO2
-
 represents a means of 
selective release of NO to  hypoxic (and presumably ischaemic) tissues and with selective 
vasodilatation in those regions, with minimal risk of inducing the “steal” phenomenon, and 
no dependence of effect on intact endothelial  function. Thus NO2
-
 represents a potential 
treatment for conditions such as myocardial ischaemia, congestive heart failure and 
pulmonary hypertension. 
A desirable characteristic of a vasodilator agent for potential use in the management of 
acutely decompensated heart failure is that it exerts marked venodilator, rather than arteriolar, 
dilating effects.  Salutary consequences of selective venodilator actions include relief of 
congestive symptoms without significant risk of precipitating symptomatic hypotension. 
Specifically, venodilator agents ameliorate the phenomenon of diastolic ventricular 
interaction, thus improving cardiac output and organ perfusion 
129, 170, 171
. 
In this regard, organic nitrates such as glyceryl trinitrate (GTN) are frequently utilized as a 
component of the management of acute heart failure with pulmonary congestion. Although 
nitrate-based therapy exerts prominent venodilator effects
172, 173
 and appears to have a 
number of advantages over a diuretic-based treatment regimen in such patients, there is no 
evidence that NO release from GTN is hypoxia-selective. Furthermore, therapy with GTN 
and other organic nitrates not only suffers the problem of attenuation of effect during 
prolonged therapy (nitrate tolerance and pseudo-tolerance) 
174, 175
, but also exhibits the 
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phenomenon of NO resistance (de novo hyporesponsiveness to all sources of NO) in the 
presence of congestive heart failure , so that some patients respond poorly to GTN, despite 
infusion at very high rates .
176-178
  Moreover, the arteriolar vasodilatation induced by organic 
nitrates such as GTN frequently induces headache and can lead to deleterious reductions in 
systemic blood pressure. 
We have described in chapter 2 the hemodynamic responses to infused NO2
-
 in normal 
subjects, documenting a marked venodilatation and modest arteriolar vasodilatation under 
normoxic conditions.  However, during hypoxia, there was selective potentiation of arterial 
vasodilation.
131
  In the current study, we have compared vasomotor responsiveness to NO2
-
 in 
stable congestive heart failure (CHF) and in normal subjects, relating response to 
concomitant plasma NO2
-
 concentrations. We theorised that CHF patients might largely 
circumvent the problem of NO resistance at the arterial level by virtue of the potentiating 
effect of tissue hypoxia on NO2
-
 bioactivation.  As such, the primary null hypothesis was that 
the vasomotor effects of nitrite would not vary between patients with CHF and normal 
subjects. The secondary hypothesis was that the pharmacokinetics of nitrite would be 
identical between the two groups. 
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3.2 METHODS 
 
Subject selection: 
The study involved a comparison between patients with stable NYHA Class II-III CHF 
(n=21) and healthy volunteers (n=20).  CHF patients were recruited from an ‘advanced heart 
failure and cardiomyopathy’ outpatient clinic. 
Among CHF patients, contraindication to study entry were therapy including long-acting 
nitrates, symptomatic hypotension and clinically significant hepatic or renal dysfunction. 
None of the normal subjects had any known coronary risk factors, and none was taking 
cardioactive medications or vitamin supplements. 
The study was approved by the Local Research Ethics Committee (Birmingham, UK), and all 
patients gave written informed consent. The study conformed to the principles of the 
Declaration of Helsinki. 
Investigations were performed in a dedicated clinical research laboratory. Subjects had 
consumed a light breakfast and abstained from caffeine drink intake for at least 6 hours. Pre-
study dietary nitrate/nitrite ingestion was not modified. 
Protocol: 
(a) Instrumentation: 
 
Subjects rested supine in a dedicated vascular laboratory with ambient temperature maintained 
between 22-24C. Twenty-gauge venous catheters were inserted into antecubital veins in each arm. A 
27-gauge arterial needle (Coopers Engineering, UK) mounted onto a 16-gauge epidural catheter and 
sealed with dental wax was inserted into the non-dominant brachial artery under sterile conditions for 
infusion of NO2
-
, and kept patent by continuous saline infusion. 
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Heart rate was monitored continuously (Dash3000, GE-Marquette). Arterial blood pressure was 
monitored continuously with finger plethysmography (TNO TPD Biomedical Instrumentation, Delft, 
Netherlands). 
 
(b) Hemodynamic assessment 
The principal hemodynamic investigations performed were serial determination of unstressed 
venous volume (UVV) as an index of venodilator response, and forearm blood flow (FBF) as 
an index of arteriolar response to infused NO2
-
. 
Both forearms were positioned on gamma-cameras (Scinton,MIA and ADAC-Transcam). 
Forearm venous volume(FVV) was assessed utilizing radionuclide plethysmography as 
previously described 
179
. In brief, venous blood was withdrawn and radio-labelled with 
Tc99m, and then re-injected into subjects after 10 minutes incubation. Images were obtained 
after an equilibration period of 15 minutes. During each cycle of data acquisition, 
scintigraphic venous vascular volumes were obtained. The venous pressure-volume 
relationship was derived from serial estimates of FVV in order to calculate UVV.  All data 
were corrected for decay of Tc99m. Results were expressed relative to baseline values of 
UVV, and those in the infused arm corrected for changes in the non-infused arm. 
FBF was measured utilizing plethysmography with mercury-silastic strain gauges (DE 
Hokanson Inc., Bellevue, Washington) as previously described
180
. Again changes in FBF 
were expressed relative to baseline values, and changes in the infused arm corrected for those 
in the non-infused arm
131
. 
Left ventricular ejection fraction was calculated by multiple gated acquisition. 
(c) NO2
-
 infusion: 
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After determination of baseline data, nitrite was infused into the non-dominant brachial artery. 
Infusion rates were 0.31µmoles/min for 30 minutes, thereafter increasing to 0.78µmoles/min, 
3.1µmoles/min and 7.8 µmoles/min, each for further 30-minute infusion periods. 
Changes in hemodynamic parameters were measured 5, 12 and 20 minutes after initiation of each 
infusion rate. 
 
(d) Blood sampling/analysis: 
Blood was withdrawn via venous cannulae in both arms at baseline and after the conclusion of 
infusion of the three higher infusion rates of sodium nitrite. 
Blood gas analysis was performed for pH, oxygen and methaemoglobin concentrations.  (Bayer 
Rapidlab 865). 
Blood for determination of venous plasma NO2
-
, nitrate and protein-bound NO (RXNO) 
concentrations (from both infused and non-infused arms) was taken into EDTA tubes and 
immediately centrifuged (200rpm for 10 minutes at 4C). Samples were stored at -80C prior to assay. 
Plasma NO2
-
 ,nitrate and protein-bound NO content were determined via ozone-based 
chemiluminescence or HPLC
181
 as previously described.
182
 
 
In order to ensure that nitrite clearance in vitro did not vary between normal subjects and patients, 
additional experiments were performed in which blood samples from normal and CHF subjects were 
spiked with sodium nitrite in vitro to final concentrations of 2 and 20µM, after which blood samples 
were incubated under gentle agitation at 37ºC with aliquots being removed after 1, 2, 5, 10, 20 and 60 
minutes prior to centrifugation and assay.  Rates of  in-vitro clearance of nitrite did not vary between 
groups (data not shown). 
 
(e) Reagents: 
Sodium nitrite was purchased from Martindale Pharmaceuticals, UK. HPLC-grade nitrite-free water 
(Fisher Scientific) was utilized for extractions and dilutions. 
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(f) Analysis of results: 
Clinical characteristics of normal subjects and CHF patients were compared utilizing non-
paired t-tests for normally distributed parameters, and Wilcoxon tests for skewed data. 
Serial changes in FBF and UVV, pH and venous O2 saturation, and concentrations of NO2
-
 and 
protein-bound NO in both the infused and non-infused forearms were compared in normal and CHF 
subjects by 2-way ANOVA with repeated measures, utilizing Dunnett’s t-test to assess for 
significance of changes at individual time points.  Logit transformation of data was utilized to detect 
possible disparity of concentration-response relationships between groups of subjects. 
All results are expressed as mean+/- SEM unless otherwise stated. 
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3.3 RESULTS 
 
Subject/Patient Characteristics 
 
These are summarised in Table 3.1 and 3.2. The normal and CHF groups differed significantly as 
regards body mass index, fasting plasma glucose and serum creatinine levels. CHF patients had both 
lower blood pressure and higher heart rates than normal subjects. 
 
Table 3.1 
 
Demographic and Clinical Features CHF Patients 
(mean±SEM) 
Healthy Controls 
(mean±SEM) 
P 
Value 
Age (y)  
Sex, M/F (%) 
Body mass index (kg/m
2
)  
Serum cholesterol (mmol/L)  
Plasma glucose (mmol/L)  
Serum Creatinine (µmol/l) 
Heart rate 
Blood pressure (mmHg) 
        Systolic 
        Diastolic 
Left Ventricular Ejection Fraction  
Aetiology (Ischaemic/DCM) 
62.9±2.7 
18/3 (86/14) 
30.0±1.2 
5.3±0.4 
5.8±0.4 
125±6.7 
74±2 
 
117±3.7 
74.8±1.9 
34.8±2.5 
10/11 
57.6±1.2 
15/5 (75/25) 
26.8±0.6 
5.4±0.2 
4.7±0.1 
103.4±5.2 
61.5±1.9 
 
128±2.0 
73.4±1.4 
56.6±1.7 
N/A 
0.08 
0.70 
0.05 
0.69 
0.05 
0.03 
0.01 
 
0.03 
0.73 
0.001 
 
 
Amongst CHF subjects, the number of patients with an ischemic basis for CHF and those due to a 
dilated cardiomyopathy were similar. Most (95%) were in Class II-III NYHA functional class. 
Treatment for CHF included ACE inhibitors/ angiotensin receptor blockers in 95%, ß-adrenoceptor 
antagonists in 76%, digoxin in 19%, and aldosterone antagonists in 57%. As planned, no patient was 
taking long-acting nitrates and none had frequent episodes of angina pectoris necessitating 
administration of sublingual GTN. 
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Table 3.2 
 
Medication % of patients receiving 
 
Beta blockers 
ACE Inhibitors / ARB 
Aldosterone Antagonists 
Loop diuretics 
 
Perhexiline 
Warfarin 
Antiplatelets 
‘Statins’ 
Digoxin 
 
 
76% 
95% 
57% 
100% 
 
29% 
57% 
48% 
52% 
19% 
 
 
Hemodynamic effects of sodium nitrite infusion 
 
Sodium nitrite infusion was well-tolerated in all subjects. Mean arterial blood pressure and heart rate 
did not vary significantly during the course of the experiment.  Maximal venous methemoglobin 
concentrations in the infused arm were less than 2% of total haemoglobin at all nitrite infusion rates. 
 
 
Forearm blood flow (FBF) changes are shown in Figure 3.1. In the non-infused forearm, both in 
normal subjects and CHF patients, there was significant vasoconstriction during the course of the 
study (ANOVA: F=2.6;P=0.04) which was attenuated at the highest nitrite infusion rate, raising the 
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possibility of the onset of NO2
-
 induced vasodilatation due to recirculation (Figure 3.1A) . In the 
infused arm (Figure 3.1B), the relationship between infusion rate and effect varied markedly between 
groups. For normal subjects, there was a progressive increase in FBF with infusion rates of 
3.14µmoles/min or greater.  On the other hand, in CHF patients, vasodilator responses were induced 
by the lowest infusion rates of nitrite, but with similar responses at > 3.14 μmoles/min.  Logit 
transformation of concentration-response data confirmed that the gradients of the linearised 
relationships were significantly steeper (P=0.017) in normal subjects than in CHF patients; partitioned 
ANOVA methodology was therefore utilized for analysis of these data. At lower, but not higher, 
infusion rates there were considerably greater FBF responses (F=5.5;P=0.02)  than those in normal 
subjects, in whom the threshold for increases in FBF was NO2
-
 infusion rate of 3.1µmoles/min. 
 
Unstressed venous volume (UVV) changes are summarised in Figure 3.2. In the non-infused arm 
(3.2A) both in normal subjects and patients, there was venoconstriction (F=9.6;P<0.0001) which was 
more marked in normal subjects (F= 15.4;P<0.001)).  In the infused arm (Figure 3.2B), both groups 
exhibited evidence of increases in UVV commencing with the lowest infusion rate of sodium nitrite 
infusion, with a monophasic and progressive dose-related increase in UVV. However, overall 
responses in CHF patients were substantially lower than those in normal subjects (F=6.3;P=0.01) . 
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Figure 3.1: Changes in Forearm Blood Flow (FBF) in the non-infused arm (A) and Infused 
arm (B) in normal subjects (open symbols) and CHF patients (closed symbols). In the non-
infused arm, FBF decreased significantly (F=2.6;P=0.04); in the infused arm there was a 
selective increase in FBF associated with lower NO2
-
 infusion rates (F=5.5;P=0.0.2). 
*=P<0.05 
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Figure 3.2: Changes in unstressed venous volume (UVV) in the non-infused arm (A) and 
infused arm (B) in normal subjects (open symbols) and CHF patients (closed symbols). In the 
non-infused arm, there was a decrease in UVV which was more marked in normal subjects 
* 
* 
Figure 3.2 
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(F=15.4;P<0.001). In the infused arm the increase in UVV with NO2
-
 infusion was attenuated 
in CHF patients (F=6.2;P=0.01). *=P<0.05 
 
Changes in pH and venous O2 saturations 
pH in venous blood did not vary significantly between normal subjects and CHF patients , nor did it 
fluctuate significantly (Figure 3.3) during nitrite infusion in either arm. 
Venous oxygen saturation also did not vary significantly between patient groups, P= 0.27 and P=0.35 
for changes in the CHF group versus healthy controls in the non infused and infused arms 
respectively.   
With nitrite infusion there was a trend to lower venous oxygen saturation with time in the non infused 
arm (P=0.07) which may be explained by immobility and decreases in blood flow with time.  In 
comparison in the infused arm there was no significant change in venous oxygen saturation with time 
(P= 0.53).  At peak dose venous oxygen saturation were 79.5% ± 7.2 and 83.4 ± 1.8 in the CHF and 
healthy volunteers respectively 
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Figure 3.3: pH fluctuations in venous blood from (A) non-infused arm and (B) infused arm 
in normal subjects (open symbols) and CHF patients (closed symbols). pH did not vary 
significantly either with NO2
-
 infusion rate or between groups. 
 
 
Plasma NO2
-
 and nitrate concentrations 
Changes in NO2
-
 concentrations in venous blood during nitrite infusion are summarised in Figure 
3.4A and 3.4B. Resting plasma NO2
-
 concentrations were non significantly (P=0.08) lower in CHF 
patients. NO2
-
 concentrations increased marginally (F=2.3;P=0.09) in venous blood in the non-infused 
arm  in both normal subjects and CHF patients (Figure 5A), with greater levels appearing 
(F=4.3;P=0.04) in the normal subject group. 
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Figure 3.4: Venous plasma nitrite concentration (µM) in (A) non-infused arm and (B) 
infused arm in normal subjects (open symbols) and CHF patients (closed symbols).  Baseline 
nitrite concentrations were marginally lower in CHF patients than in normal subjects 
(P=0.08). Nitrite concentrations rose significantly (F=32.7;P<0.0001) with NO2
-
 infusion in 
the infused arm: this increase  was attenuated significantly (F=10.6;P=0.002) in CHF 
patients. 
 
In  the infused arm (Figure 3.4B), NO2
-
 concentrations increased approximately 70-fold during nitrite 
infusion (F=32.7;P<0.0001;Figure 3.3B).  The increase in venous NO2
-
 levels in the infused arm was 
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greater in the normal subjects than in CHF patients (F=10.6;P=0.002).  The increase in venous NO2
- 
concentrations for a 10-fold increase nitrite infusion rate increase was disproportionately small: 
approximately 7-fold for normal subjects and 3-4 fold for CHF patients. 
Consistent with previous observations 
183
 basal nitrate levels in the venous effluent were found to be 
higher in the CHF patients compared to healthy volunteers (P=0.0034).  Venous nitrate levels rose 
similarly (P= 0.96 and P=0.67 for the non infused and infused arms respectively) in the two groups of 
subjects (Figure3. 5A and 3.5B) suggesting that the degree of oxidation of nitrite to nitrate did not 
differ between groups. 
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Figure 3.5: Venous plasma nitrate concentrations in (A) non infused arm and (B) infused 
arm in normal subjects (open symbols) and CHF patients (closed symbols).  Baseline nitrate 
concentrations were greater (P=0.003) in CHF subjects.  During nitrite infusion, nitrate 
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concentrations increased (F=16.2 P<0.0001)) in the infused arm, but without significant 
difference between normal subjects and CHF patients. 
 
Protein-bound NO concentrations 
 
Changes in protein-bound NO concentrations in venous blood from non-infused and infused arms 
throughout the study are summarised in Figure 3.6A and 3.6B.  In the non-infused arm (Figure 3.6A), 
protein-bound NO concentrations were significantly greater in normal subjects than in patients with 
CHF (F=8.6; P=0.04).  In the infused arm, this difference was attenuated during nitrite infusion, 
becoming non-significant. Furthermore, protein-bound NO tended to increase with the highest nitrite 
infusion rate. 
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Figure 3.6:  Venous plasma protein-bound NO (RXNO:nmol/L) in (A) non-infused arm and 
(B) infused arm in normal subjects (open symbols)and CHF patients (closed symbols). 
RXNO concentrations did not vary significantly with NO2- infusion in either arm (F= 0.44 
P= 0.99), but were significantly lower in CHF patients than in normal subjects in the non-
infused arm (P=0.04), while this difference was attenuated in the infused arm. 
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3.4 DISCUSSION 
 
A number of previous studies, both in humans and animal models, have suggested that infused nitrite 
exerts vasomotor responses which are in many ways similar to those of the organic nitrates, with  
marked venodilatation, and moderate arteriolar dilatation which becomes more marked at  high 
infusion rates or when augmented by hypoxia or exercise.
131, 184
 These characteristics suggest that, like 
organic nitrates, NO2
-
 is selectively bio-activated to NO in veins and large arteries.  On the other hand, 
infused NO2
-
 represents in many ways a particularly attractive agent for treatment of CHF 
complicated by fluid overload.  Not only is it a potent venodilator, but also its effects appear to be 
(somewhat surprisingly) independent of the phenomenon of tolerance induction 
46
, at least in primate 
models. Furthermore, NO2
-
 provides a “needs-based” vasodilator effect, with effects accentuated by 
hypoxia in many systems 
76, 185, 186
. The multiple/precise mechanism(s) underlying this accentuated 
effect remain incompletely elucidated. 
 
In this study, effects of nitrite infusion were compared in cohorts of normal subjects and patients with 
stable CHF without fluid overload.  The previously documented
131
 selective venodilator effects of 
NO2
-
 at low infusion rates was again documented in normal subjects: the lowest two infusion rates of 
nitrite induced significant increases in UVV, without any change in FBF. On the other hand, CHF-
patients exhibited marked and selective hyper-responsiveness to lower rates of NO2
-
 infusion at the 
level of the forearm resistance vessels, whereas there was also evidence of substantially reduced 
venodilator responses in CHF patients. The latter finding may represent NO resistance. Alternatively 
it may be a consequence of increased clearance of NO2
-
 across the vascular bed, resulting in lower 
concentrations in the capacitance vasculature at any given infusion rate (see below).  
The finding that CHF-patients had lower protein-bound NO and marginally lower nitrite 
concentrations than normal subjects is consistent with previous findings in subjects with endothelial 
dysfunction
42, 187, 188
.  Steady-state NO2
-
 concentrations (in the absence of dietary or intravenous NO2
-
 
supplementation)  may be regarded as being indicative of NO generation  and therefore indicative of 
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diminished eNOS activity in CHF
42
, whereas protein-bound NO concentrations reflect  both the 
generation of S-nitrosoproteins  from released NO, as well as a measure of prevalent redox stress
189
. 
With sodium nitrite infusion, venous NO2
-
 concentrations increased, but not in proportion to the 
increases in infusion rates, suggesting some selective loss of NO2
-
 during sampling at higher infusion 
rates. These changes were noted both in the infused and non-infused arms, indicating that the non-
infused arm cannot be regarded as a simple “control” site: indeed the FBF changes (Figure 3.1, Inset) 
suggest the onset of some dilator effect with the highest nitrite infusion rate. Nevertheless, NO2
-
 levels 
increased far less markedly with increasing sodium nitrite infusion rates in CHF patients than in 
normals (Figure 3.5B) indicating greater rates of NO2
-
 clearance in these patients. Although NO2
-
 may 
be reduced to NO (bio-activation), a major clearance mechanism for NO2
-
 is oxidation to nitrate. 
Therefore, venous nitrate concentrations were measured in both infused and non-infused arms, 
revealing a similar increase in plasma nitrate levels in the two groups upon infusion of nitrite and thus 
making clearance through oxidation to nitrate less likely.  Similarly our in vitro results suggest that 
there is no systematic difference in the rate of degradation of nitrite in the two groups, thus excluding 
sampling artefacts as a possible explanation for the differences in nitrite concentrations between 
normal subjects and CHF-patients.
 
 As regards the additional potential formation of S-nitrosoproteins via NO2
-
 metabolism, 
venous protein-bound NO concentrations tended to increase in the infused arm in the CHF 
patients (coupled with a relative decrease in protein-bound NO concentrations in the 
controls), attenuating the difference between baseline levels in the two groups. These findings 
are also consistent with selective bio-activation of NO2
-
 in the CHF patients, and might have 
been accounted for by the presence of tissue hypoxia and/or acidosis in these patients, given 
the previously described incremental bio-activation of NO2
-
 in the presence of hypoxia
131
. 
However, neither venous blood pH nor oxygen concentrations differed significantly between 
groups. There was a trivially (non significantly) lower venous oxygen saturation in the 
infused arm of the heart failure patients but this seems unlikely to provide an explanation for 
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the difference in clearance. It therefore appears either that a component of  
subcellular/microvascular hypoxia was present in the CHF patients without detection in 
venous samples (a possible but somewhat unlikely event) or that these results indicate that, 
apart from hypoxia, NO2
-
 bioactivation to NO can be induced by factors other than hypoxia, 
such as changes in redox state. This issue is worthy of further investigation.  
Taken together, these results show that CHF patients are hyper-responsive to the arteriolar dilating 
effects of infused sodium nitrite, presumably due to increased release of NO (despite the absence of 
arterial hypoxaemia). This finding may imply the need for some caution in the use of infused nitrite 
preparations in patients with decompensated CHF, for fear of precipitating falls in systolic blood 
pressure. On the other hand, symptomatic hypotension was not observed in the currently studied 
patient cohort. 
However CHF patients were hyporesponsive both to the effects of infused sodium nitrite on venous 
capacitance and to a lesser extent, to the effects on FBF at high infusion rates. These findings may 
imply the existence of NO resistance, as previously documented in both arteries and platelets of such 
patients
176
. Although platelet NO resistance exhibits partial responsiveness to ACE inhibitor 
therapy
190
, which was utilized in the majority of the CHF group, its interaction with vascular NO 
resistance is less certain. Alternatively the apparent resistance of the capacitance vessels may in part 
be due to a lower concentration of nitrite in venous blood due to the increased transvascular clearance. 
As net responsiveness to NO2
-
 reflects both accelerated bioactivation and diminished tissue responses 
to NO, it is likely that individual responses might well vary markedly, according to each of these 
component factors. 
 
A number of potential limitations and caveats apply to the current findings. Most importantly, the 
biochemical basis of the observed arterial hyper-responsiveness to NO2
-
 was not determined, and 
indeed the possible relevance of tissue hypoxia to this phenomenon cannot be completely excluded 
with the methodology utilized in this study. Furthermore, changes in tissue redox stress were not 
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documented: this remains a major priority for future investigations. While the observation of 
attenuation of the increase in plasma NO2
-
 in association with increasing rates of sodium nitrite 
infusion implies accelerated transvascular clearance of NO2
-
 in such patients, the release of NO was 
not measured, and therefore it cannot be absolutely certain that there was a close relationship between 
such accelerated clearance and incremental rates of NO generation. Indeed, there is recent evidence 
both that nitrite may exhibit vasoactivity independent of bioconversion and that nitrite may exert a 
component of its effects independent of the formation of NO or NO adduct
191
. Furthermore, the 
proportion of nitrite clearance via oxidation to nitrate cannot be assessed completely from the current 
results, although it was possible to exclude the possibility that transvascular nitrate generation 
occurred selectively in CHF patients given the similar rise in nitrate levels. Finally, the findings of the 
current investigation, while relevant to the potential therapeutic administration of nitrites, may not be 
indicative of physiological modulation of NO2
-
 effect at far lower concentrations. 
While NO2
- 
 infusion has the potential to lead to the generation of methemoglobin, (a possible 
concern) we did not observe a significant increase in venous methemoglobin levels in this 
study.  
We noted a significant vasoconstriction in the non-infused arm during the study.  In theory 
this could have been secondary to hypotension however no significant drop in blood pressure 
was observed, in fact there appeared to be a trend towards an increase.  It has been our 
experience in prolonged intrabrachial infusion studies with other agents that forearm blood 
flow falls in the contralateral arm over time despite no significant changes in blood pressure. 
We suspect this results from the effects of slight discomfort and often a full bladder during 
these long studies.  It is because of such changes in flow in the non infused arm during 
prolonged studies that bilateral plethysmography with correction for the non infused arm is 
recommended for intrabrachial infusion studies.
192
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With regards to the medication received by the CHF patients, while there are data to suggest 
that angiotensin converting enzyme inhibitors and angiotensin receptor blockers  improve NO 
production/ endothelial function we could not find any evidence to suggest any impact upon 
nitrite conversion.  The possibility that the medication taken by the CHF patients may 
account for some of the differences observed remains a limitation of this study. 
 
 
The findings of the current investigation extend the question of the potential clinical utility of NO2
-
   
as a component of the management of patients with both acute and chronic heart failure. The major 
residual issue to be explored is the extent of change in vascular responsiveness to be seen in such 
patients, especially in decompensated CHF, where significant tissue hypoxia is more likely to be 
present,  with resultant potentiation of NO2
-
-  bio-activation, perhaps counter-balanced in part by the 
phenomenon of tissue resistance to NO 
193
.  Despite the occurrence of NO resistance, treatment with 
organic nitrates is at least as effective as diuretic/morphine-based acute pharmacotherapy for 
decompensated heart failure with acute pulmonary edema 
194, 195
.  However, nitrate therapy is often 
associated with the unpleasant side effect of headache.  In this study none of the subjects who 
received intravenous nitrite suffered with this symptom and potentially provides a distinct advantage 
over traditional nitrate therapies. A comparison with NO2
-
 based therapy now seems indicated.  
 
 
  
Having established the vascular response to nitrite in both health and heart failure subjects we 
now turned to investigating the mechanisms involved in nitrite reduction.  We focussed 
specifically on two enzyme systems that had been proposed as being critically involved on 
nitrite conversion to NO. 
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Chapter 4 
 
Xanthine Oxidoreductase and Endothelial Nitric Oxide Synthase Do 
Not Contribute Significantly To Vascular Relaxation by Nitrite in 
Man  
 
 
 
The data presented in this chapter is currently being considered for publication in the journal 
“Clinical Science”.  
 
 
 
 
 
Execution 
I performed all of the recruitment and organisation of the appointments involved in the study.  I 
performed assessment of forearm blood flow, radionuclide plethymography and radionuclide 
ventriculography studies in the University of Birmingham.  Biochemical analysis was performed by 
Dr Phil James and his team at the University of Cardiff, Wales. 
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Abstract 
 
Aims: The nitrite anion is increasingly considered an important source of bioactive nitric 
oxide. Recent evidence suggests that xanthine oxidoreductase (XOR) and endothelial nitric 
oxide synthase (eNOS), in both vasculature and erythrocytes, may reduce nitrite to NO ex 
vivo under conditions of severe hypoxia/acidosis. To ascertain the importance of this 
mechanism in man, the effect of nitrite infusion with and without blockade of NOS and XOR, 
was studied in 25 healthy volunteers.   
 
Methods : Uniquely effects of intra-brachial nitrite infusion on both the high and low ambient 
oxygen tension environments of resistance vessels and the capacitance bed, respectively, 
were studied.   
 
Results:  Peak percentage venodilation with nitrite and L-NMMA was 15.1% compared to 
26.8% with nitrite alone, the difference being consistent with inhibition of pre-existing basal 
eNOS activity alone. Peak FBF-ratio(FBFr) was also similar, 40.4% and 42.7%, with and 
without eNOS inhibition respectively. Peak percentage venodilation in the allopurinol group 
(26.9%) was not different to controls(26.8%). Peak FBFr was also similar in the two groups, 
51.8% and 42.7%, with and without XOR inhibition respectively.   
Conclusion:   In healthy volunteers at rest, neither intravascular XOR nor eNOS appear to 
play a significant role in nitrite-induced vasodilatation, in either high or lower ambient 
oxygen tension environments.   
 
Key words: Nitric oxide, nitrite, vasodilation, xanthine oxidoreductase and nitric oxide 
synthase 
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4.1 Introduction 
 
A number of important questions include: (i) what are the nitrite reductase(s) in vivo; (ii) how 
do these reductase(s) interact with endogenous/exogenous nitrite to elicit biological effects in 
vivo and (iii) what are the corresponding therapeutic implications? 
 
A variety of different nitrite reductases have been identified. These include pH-dependent 
enzyme-independent nitrite conversion to NO,
47
 deoxyhemoglobin,
48-54
 myoglobin,
55-59
 
neuroglobin,
60
 aldehyde oxidase,
61
 microsomal cytochrome P-450
62
 and cytochrome C.
63, 64
, 
however the relative importance of these different mechanisms in vivo remains unclear. Since 
the different proposed reductases exhibit tissue specificity, synergy, redundancy and 
sensitivity to incipient conditions
66
; and since nitrite is reduced via  a number of mechanisms 
ex vivo, there are significant challenges to translating in vitro nitrite reducing capacity to in 
vivo physiology. For example, there has been controversy regarding the role of red blood 
cells (RBCs), hemoglobin (Hb) and deoxyhemoglobin in nitrite metabolism.
48-54, 67-69
 
Although there is a clear chemical rationale for the Fe
II
 centre of Hb to reduce nitrite, the NO 
scavenging capacity of the plentiful heme groups in RBCs has led to  ongoing discussion 
regarding  their likely net NO yield.
61
  To reconcile this discordance, the membrane 
compartment hypothesis contends that RBC membrane eNOS and XOR generate NO at a 
distance from the RBC heme, hence the NO is free to diffuse to the vasculature. 
 
Similarly, building on existing evidence that the vasculature has intrinsic nitrite reductase 
activity,
70
 and that XOR and eNOS have been implicated as nitrite reductases for several 
years;
58, 59, 61, 68, 70-72
, it has recently been  reported  that nitrite conversion to NO by the 
vasculature and/or by RBCs is attenuated by inhibition of xanthine oxidoreductase (XOR) at 
very low oxygen tensions at pH 6.8. Furthermore, it has been shown that RBC endothelial 
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nitric oxide synthase (eNOS) inhibition with L-NMMA diminishes nitrite bioconversion.
73
  
These proposals have merit as they reconcile the long held belief that RBCs yield NO with 
the concern that high RBC Hb concentrations would attenuate NO release through 
scavenging.  However, while these findings may be applicable to nitrite bioconversion in the 
context of pronounced pathological hypoxia, the implication of these observations to the 
vasodilation observed with pharmacological concentrations of nitrite under normoxic and 
mildly hypoxic conditions is unclear.  
 
Accordingly, although the role of XOR
68
 and NOS
54
 have been studied to some extent, 
hitherto such studies have been limited to investigating the resistance bed, yet the 
mechanisms responsible for nitrite induced vasorelaxation may differ according to the 
prevailing oxygen tension.   
 
In order to test the role of XOR and eNOS in nitrite reduction in vivo in normal resting non-
pathological conditions in man, we used well-established pharmacological inhibitors of these 
enzymes, at doses shown to provide sufficient blockade in healthy volunteers. More 
specifically we study the role of XOR and eNOS in mediating nitrite-induced vascular effects 
in both the high oxygen tension environment of the forearm resistance bed but also, and more 
importantly the role in the relatively hypoxic environment of the capacitance vessels.  We 
employ a similar experimental set up to that used in earlier chapters.  We infused sodium 
nitrite intra-brachially with and without enzyme inhibition in order to ascertain the extent to 
which XOR and eNOS are contributing to NO generation from nitrite in both the resistance 
and capacitance beds.  
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4.2 Materials and Methods 
 
Subject Recruitment 
25 healthy volunteers were recruited; 15 to the NOS group and 10 to the XOR group. They 
were non-smokers with no history of hypertension, diabetes or hypercholesterolemia, and no 
family history of ischemic heart disease. None was taking cardiac medications or vitamin 
supplements and all had a normal cardiovascular examination and electrocardiogram.  
 
Ethical Statement 
The study was approved by the Local Research Ethics Committee and all subjects gave 
written informed consent.  The study complied with the Declaration of Helsinki. 
 
Subject preparation and Measurement of Forearm Blood Flow 
Subjects rested supine in a dedicated vascular laboratory (22-24°C). A 27-gauge arterial 
needle (Coopers Engineering, United Kingdom) mounted onto a 16-gauge epidural catheter 
and sealed with dental wax was inserted under sterile conditions into the non-dominant 
brachial artery. Heart rate and rhythm (Dash 3000, Marquette, GE) and blood pressure (finger 
plethysmography: TNO TPD Biomedical Instrumentation, Delft, Netherlands) were 
monitored continuously. Forearm blood flow (FBF) was measured using mercury-in-silastic 
strain gauges (D.E. Hokanson, Inc., Bellevue, Washington).
196
 In order to control for 
systemic and local passive changes with time changes in FBF observed were corrected for the 
control arm and thereby expressed as a FBF ratio. 
 
Measurement of Forearm Venous Volume  
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Forearm venous volume (FVV) was assessed using radionuclide plethysmography, as 
described previously.
197
 The advantage over strain gauge plethysmography is that results are 
independent of changes in interstitial fluid. 1 minute dynamic images were obtained in both 
arms using two gamma cameras (Scintron, MIA and ADAC-Transcam). Since >90% of the 
injected isotope remains intravascular, and the vast majority of blood in the peripheral 
circulation is venous, changes in counts reflect changes in FVV.
197
 Vascular volumes were 
plotted against upper arm cuff pressures (of 0, 10, 20 and 30mmHg) to form a venous 
volume-pressure relationship (VPR). Linear regression was applied to each VPR, with 
R
2
>0.9 taken to indicate linearity. Non-linear VPRs were discarded. Volumes were expressed 
as a percentage of the unstressed venous volume during normal saline infusion (the volume-
axis intercept). A parallel shift of the relationship indicates a change in venous tone.
197
 Our 
previous studies have shown that changes in arterial inflow do not alter venous VPR.
197
 As 
with FBF, data were adjusted for changes in the control arm and corrected for physical decay 
of technetium. We, and others, have previously validated this technique.
197-199
 
 
Inhibition of Nitric Oxide Synthase (n=15) 
(i) Intra-brachial sodium nitrite was given at the dose of 7.84µmol/min for 30 minutes.  FVV 
and FBF were measured a 20 minutes.  60 minutes was allowed to elapse for a return to 
baseline. L-NMMA alone was then infused at a dose of 12mg/min for a total of 20 minutes. 
L-NMMA and nitrite (7.84µmol/min) were infused concurrently for 20 minutes.  This dose of 
L-NMMA has previously shown to provide local NOS blockade.
200
 Moreover, this achieved a 
calculated arterial blood concentration of LNMMA of 4mmol/l, slightly higher than that 
previously shown to substantially inhibit red blood cell nitric oxide synthase activity 
(3mmol/l). 
201
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Inhibition of Xanthine Oxidase (n=10) 
Each subject received 600mg oral allopurinol at 6am on the morning of the study, a dose 
demonstrated to provide >95% inhibition of XO.
202-204
 Subjects were otherwise prepared as in 
the eNOS inhibition group. Intra-brachial sodium nitrite was given at a dose 7.84µmol/min; 
FVV then FBF were measured at 5, 12 and 20 minutes. 
 
Data and Statistical Analysis 
Data were analyzed using SPSS version 14 for Windows. All data are expressed as mean ± 
SEM, and P<0.05 was considered statistically significant. One-way analysis of variance 
(repeated measures) was carried out for changes in FBF and FVV.  Data was found to be 
normally distributed. 
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4.3 Results 
Subject characteristics  
Grouped baseline characteristics for all subjects are shown in Table 4.1.   
 
Table 4.1 – Subject Characteristics 
 
Demographic and Clinical Features   (mean ± s.e.m.)  
Age (y)  
Sex, M/F 
Body mass index (kg/m
2
)  
Serum cholesterol (mmol/L)  
Plasma glucose (mmol/L)  
Serum Creatinine (µmol/l) 
Heart rate 
Blood pressure (mmHg) 
        Systolic 
        Diastolic 
Left Ventricular Ejection Fraction  
 
 57.6 ± 1.2 
21/4 
26.8 ± 0.6 
5.4 ± 0.2 
4.7 ± 0.1 
103.4 ± 5.2 
61.5 ± 1.9 
 
128 ± 2.0 
73.4 ± 1.4 
56.6 ± 1.7 
 
 
 
 
NOS inhibition reduced baseline venodilation and peak nitrite-induced venodilation to a 
similar extent 
L-NMMA alone caused a downward displacement of the basal VPR (venoconstriction) of 9.9 
± 2.8% (P=0.07) (Fig.4.1). This is consistent with inhibition of basal NO production and with 
previous observations. Nitrite (7.84µmol/min) alone caused an upward displacement of the 
VPR (venodilation) of 26.8 ± 4.6% (P=0.004). Nitrite (7.84µmol/min) and L-NMMA caused 
an upward displacement of the VPR of 15.1 ± 2.5% (P=0.011). The difference was 11.7 ± 
2.1%, P=0.16 between groups.  
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Figure 4.1 – NOS inhibition and FVV 
eNOS inhibition with L-NMMA reduced baseline FVV and peak nitrite-induced venodilation 
by a similar amount. **P<0.01 compared to baseline, n=9. 
 
 
NOS inhibition did not affect resistance bed response to nitrite 
L-NMMA alone caused a 20% reduction in the basal FBF ratio (vasoconstriction), from 1.0 ± 
0.02 to 0.8 ± 0.02 (P=0.001 by one-way ANOVA). Nitrite (7.84µmol/min) alone increased 
the FBF ratio (i.e. vasodilation) by 42.7% (from 1.00 ± 0.02 to 1.39 ± 0.08, P=0.007). Nitrite 
(7.84µmol/min) and L-NMMA increased the FBF ratio by 40.4% (from 1.0 ± 0.02 to 1.37 ± 
0.11, P=0.032) (Fig.4.2). P=1.00 between groups. 
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Figure 4.2 – FBFr and NOS inhibition 
eNOS inhibition with L-NMMA did not alter the resistance vessel response to nitrite. 
*P<0.05 compared to baseline; **P<0.01 compared to baseline, n=9.  
 
 
Xanthine oxidase inhibition did not affect nitrite-induced venodilation 
In subjects pre-treated with the xanthine oxidase inhibitor allopurinol, nitrite (7.84µmol/min) 
caused an upward displacement of the VPR of 26.9 ± 3.8% compared to baseline (P=0.011) 
(Fig.4.3) as compared to an upward displacement of the VPR of 26.8 ± 4.6% in controls 
(P=0.004) (Fig.4.3). P=0.30 between groups.  
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Figure 4.3 - XOR inhibition and FVV 
XOR inhibition with allopurinol did not affect nitrite induced venodilation. *P<0.05 
compared to baseline, n=10; **P<0.01 compared to baseline, n=9.  
 
 
 
Xanthine Oxidase inhibition did not affect resistance bed response to nitrite 
In subjects pre-treated with allopurinol, 7.84µmol/min nitrite increased the FBF ratio by 
51.8% (to 1.5 ± 0.1, P=0.021) (Fig.4), as compared to an increase in the FBF ratio of 42.7% 
(from 1.00 ± 0.02 to 1.39 ± 0.08, P=0.007) with 7.84µmol/min nitrite alone. P=0.50 between 
groups. 
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Figure 4.4 - FBFr and XOR inhibition 
XOR inhibition with allopurinol did not affect resistance vessel response to nitrite, compared 
to controls. *P<0.05 compared to baseline, n=10 for allopurinol, n=8 for controls. 
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4.4 Discussion 
 
The principal finding of the present study is that XOR and eNOS, irrespective of their cellular 
location, do not significantly contribute to nitrite-induced vasodilatation in vivo in healthy 
human volunteers under the conditions of this study. Our observations pertain to both 
resistance and capacitance vessels, and are based on the use of allopurinol and L-NMMA, 
which are well-established inhibitors of XOR and eNOS.  
 
Role of NOS as a nitrite reductase 
NO has a central role in maintaining basal vascular tone as evidenced by the observations that 
intra-arterial NOS inhibitors reduce resting blood flow
205
 and that mice lacking eNOS exhibit 
increased vascular tone (as  manifested by their hypertension).
206
 This crucial role of vascular 
eNOS and NO in vasoregulation
207
, coupled with the capacity of the vasculature to 
bioconvert nitrite,
61, 70
 converged to proposals that nitrite may be reduced by eNOS ex and in 
vivo. Moreover, there is increasing evidence that RBCs express biochemically active eNOS 
on the cytoplasmic surface of their membranes. Accordingly, it has been reported ex vivo that 
RBC eNOS, at concentrations of nitrite closer to the physiological range represents a source 
of nitrite derived NO free from scavenging by intracellular oxyHb. Thus while RBCs may in 
the context of severe acidosis (pH = 6.8) liberate NO from nitrite, the results of the present 
study do not support such a role for eNOS under less extreme conditions (i.e. L-NMMA did 
not inhibit nitrite-induced vasodilatation in vivo). In arteries and in the mildly hypoxic 
environment of veins the reduction in the venodilator effect of nitrite by co-infusion of L-
NMMA was equivalent in magnitude to the effect of L-NMMA on basal venous tone
138
. At 
most eNOS therefore makes only a modest contribution to nitrite-induced venodilation (20% 
or less, and probably none) under physiological conditions. 
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In order to reconcile the observations made in previous studies with our observations, we 
note that: (i) The concentrations of nitrite often used ex vivo  (e.g.100µM) are 1-2 orders of 
magnitude greater than both those occurring in vivo (0.2-5µM) or the vasodilating nitrite 
levels identified in previous studies (<10µM).
208
 In the present study, while the initial nitrite 
dose was similarly high(~50µM)
208
, nitrite-induced vasodilatation persisted as levels fell to 
near physiological concentrations. (ii) Ex vivo hypoxia is established by purging of 
experimental chambers with N2, yielding very low PO2 levels (2-4mmHg). By contrast, in 
health (at rest), venous oxygen tension is typically around 70 -80mmHg. At physiological 
oxygen tensions in vivo, oxygen concentrations are not limiting for eNOS (Km 6-9 µMol). 
Thus while eNOS-related nitrite conversion may be of pertinence to severe hypoxia 
(anaeorobiosis and acidosis), biochemical considerations would not readily explain such a 
role in vivo under relatively normal circumstances.  (iii) Simlarly, the pH yielding maximal 
NO elaboration ex vivo studies  (~6.8) is extreme. (iv) Finally,RBC NO production, while 
potentially of importance in very severe hypoxia and acidosis, is approximately 10-fold less 
than that of blood vessels. Mitigating this lesser RBC NO production, it is recognized that in 
the context of hypoxia, NO donors appear to have a greater gain in activating cGMP (i.e. 
hypoxia increases NO bioavailability).  
 
Role of XOR as a nitrite reductase 
Xanthine oxidoreductase is a potential nitrite reductase.
59, 61
 Whilst the present study does not  
exclude a role for XOR as a vascular reductase in pathological states, it does not support the 
proposal that XOR is a major in vivo reductase in  healthy human volunteers under 
normoxic/mildly hypoxic conditions. Indeed, the demonstrated contribution by XOR to (rat 
vascular) NO production is less than 25%. This is consistent with recent biochemical data 
showing that heme proteins are the principal nitrite reductases.
209
 Methodological differences 
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may again have contributed to the discrepancy between our findings and those of ex vivo 
studies. These include the high concentration of nitrite, low pH (~5.5), and low oxygen 
tension used in these studies.  
 
4.5 Limitations 
 
The present study has a number of limitations.  
The dose of nitrite used is an order of magnitude greater than that present in normal 
physiology. We did however note that vasodilatation persisted into a period where nitrite 
concentrations were close to physiological concentrations. Moreover, the focus of the present 
study was the effect of exogenous nitrite.  
Our interpretation of the effect of L-NMMA depends upon the subtraction of the effect of this 
non-specific NOS inhibitor on baseline flow. We have previously shown that infusion of L-
NMMA alone leads to a 10% reduction in FVV, which has been interpreted as being due to 
an inhibition of basal NO production.  It is however possible that a component of this may be 
due to the production of NO by NOS using nitrite as a substrate.  Although this is a limitation 
of the study we feel that this is unlikely given that the magnitude of the venodilatation is not 
blunted once the 10% adjustment is made. 
 
4.6 Conclusion 
 
Many proteins, especially those with an established capacity for electron transfer (e.g. hemes, 
cytochromes, molybdenum dependant oxidoreductases etc), can reduce nitrite. Although the 
chemistry of these reduction reactions will vary and are interesting in their own right, there is 
an increasing focus on what does reduce nitrite in vivo.  Our results are best seen as being 
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complementary to those of Webb et al.
168
  While the nitrite reductase activity of eNOS and 
XOR may be relevant and important in pathological states, our in vivo studies in man would 
suggest that in resting healthy volunteers, eNOS and XOR do not play a significant role.  
Focus will therefore return to other contenders in the field including deoxyhaemoglobin and 
more recently haem containing proteins in the vascular wall. 
 
 
Whilst conducting these studies we observed a phenomenon which initially caused some 
confusion and which had not been hitherto described.  We observed that both the arterial and 
venous responses to nitrite endured despite plasma levels having dropped close to those at 
baseline. These observations are described in more detail in the following chapter.   
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Chapter 5 
 
 
The Persisting Vascular Effects of Intra arterial Nitrite 
 
This data has been presented at The 57th Annual American College of Cardiology (ACC) scientific 
sessions, March 2008: 
 
 Maher AR, Thomas P, Anderson S, Abozguia, Ahmed I, Weaver R, James P, Frenneaux MP.  
Intra-arterial causes an enduring Vasodilation in Man.  The 57
th
 Annual American College of 
Cardiology (ACC) scientific sessions, March 2008, Chicago, USA 
 
 
Execution 
I performed all of the recruitment and organisation of the appointments involved in the study.  I 
performed assessment of forearm blood flow, radionuclide plethymography and radionuclide 
ventriculography studies in the University of Birmingham.  Biochemical analysis was performed by 
Dr Phil James and his team at the University of Cardiff, Wales. 
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Abstract 
 
Background:  We present the important observation that the vascular effects of nitrite 
following an intra-arterial infusion persist long after the intravascular concentration of nitrite 
has returned to levels close to baseline.   
 
Methods: 17 Healthy volunteers were studied while either breathing room air or 12% oxygen. 
Following saline, sodium-nitrite was infused intra-arterially at 7.84µmol/min followed by an 
hour-long saline infusion. At each stage Forearm Blood Flow (FBF), Forearm Venous 
Volume/Pressure relation (an index of venous tone) and plasma levels of NO metabolites 
were assessed.  
 
Results:  Following cessation of nitrite infusion venodilation persisted for up to 30 minutes 
whereas venous nitrite levels had decreased from a peak of 48.9 microM to 4.4microM by 
15minutes. Arterial blood flow expressed as FBF-ratio (FBFR), increased from baseline to 
1.50±0.16 (P<0.05) and 1.99±0.17 (P<0.01) in normoxia and hypoxia respectively and 
returned to baseline only at 45 minutes and 15 minutes respectively. 
 
Conclusions: We demonstrate a persisting effect of nitrite long after the intravascular levels 
have decreased suggesting a significant degree of protein binding.  We propose that protein 
binding of NO in vessels (possibly by myoglobin) may be responsible.  Our data may provide 
new insights into the role of nitrite in vascular physiology. 
Key words: Nitric oxide, nitrite, veins, hypoxia, myoglobin 
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5.1 Introduction 
 
Herein I focus on a fascinating aspect, namely the time-course of vasodilation post the 
termination of the nitrite infusion.  We show that this vasodilation persists for an 
unexpectedly long period of time.  This observation appears to be in distinct contrast to the 
phenomenon of rebound vasoconstriction that has been observed with nitrates and implicated 
in the ischaemia seen in patients taking nitrates during their ‘nitrate-free period’.210  Rabbits 
treated with glycerin trinitrate exhibit an increased coronary resistance after abrupt 
withdrawal.
211
 
 
We have previously reported the acute effects of local nitrite infusion.  We showed that in 
normoxia nitrite was a potent venodilator but had little effect on resistance vessels.  However, 
in hypoxia nitrite became a potent arteriolar-dilator.  We now present data on the persistence 
of this effect following cessation of nitrite infusion despite normalisation of nitrite levels.   
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5.2 Methods 
 
Subjects 
Seventeen healthy volunteers were studied.  All subjects had no history of active smoking, 
hypertension, diabetes or hypercholesterolemia and no family history of ischemic heart 
disease. None of the healthy volunteers was taking cardioactive medication or vitamin 
supplements and all had a normal cardiovascular examination and electrocardiogram. All 
subjects gave written informed consent. The study was approved by the Local Research 
Ethics Committee. Studies were performed at the University of Birmingham Clinical 
Research Block in a dedicated vascular laboratory (22 to 24°C) and with the subject having 
had a light breakfast and abstained from caffeine for at least 6 h previously.  
 
Biochemistry 
Chemicals and reagents 
All chemicals were purchased from Sigma other than glacial acetic acid, HPLC grade nitrite 
free water and hydrochloric acid (Fisher Scientific). Sodium nitrite was purchased from 
Martindale Pharmaceuticals, UK. 
 
Ozone-based chemiluminescence 
Plasma nitrite and protein-bound NO were measured using a tri-iodide reagent linked to 
ozone based chemiluminescence as described previously.
142
  The tri-iodide reagent is 
probably the most widely used in the NO metabolite field and has been validated against 
standards in several laboratories.
5, 143-146
  The reader is referred to a complete discussion of 
the assay.
33, 45, 142, 147-151
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A stock solution of tri-iodide reagent was prepared fresh each day.
142, 146
 Immediately prior to 
analysis frozen plasma samples were thawed in a water bath at 37°C for 3 minutes.  We have 
previously shown sample freezing has no effect on plasma NO metabolite stability.
152
  Area 
under curve was used in analysis and concentrations were calculated from a standard curve of 
sodium nitrite. 
 
Study Protocols 
 
In vivo studies 
FVV was assessed using radionuclide plethysmography. The details of the technique and its 
relative merits for assessing venous capacitance are detailed elsewhere.
139
 
Subjects rested supine.  Both forearms were positioned on the face of a gamma camera 
(Scintron, MIA and ADAC-Transcam).  A 20-gauge cannula was inserted into an ante-cubital 
vein in each arm.  Venous blood was drawn and sent for a Full Blood Count and Biochemical 
Profile. A 27-gauge arterial needle (Coopers Engineering, United Kingdom) mounted onto a 
16-gauge epidural catheter, sealed with dental wax, was inserted into the non-dominant 
brachial artery under sterile conditions and kept patent by the continuous infusion of normal-
saline. 
 
Heart rate and rhythm were monitored continuously (Dash 3000, Marquette, GE) as was 
blood pressure with finger plethysmography (TNO TPD Biomedical Instrumentation, Delft, 
Netherlands).  Mercury-in-silastic strain gauges were applied to measure FBF (D.E. 
Hokanson, Inc., Bellevue, Washington), as described previously.
153
  Fifteen minutes after the 
administration of the radio-labeled red blood cells two venous Volume Presure Relationships 
(VPR) were recorded and FBF were assessed. Blood was drawn from both venous cannulae 
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at each stage of the study. Samples were collected in 5mL syringes and transferred into 4ml 
EDTA collection tubes.  These were centrifuged at 2000rpm for 10 minutes at 4
0
C.  The 
plasma was snap frozen in liquid nitrogen and stored at -80ºC until analysis for plasma nitrite 
and protein-bound NO. 
The study proceeded with the subject either breathing room air (9 subjects) or 12% oxygen (8 
subjects). 
In the subjects breathing 12% oxygen the study continued when arterial oxygen saturation 
levels were stable in the range 83-88%. 
Oxygen saturation levels were monitored continuously using pulse-oximetry (Nellcor N-180). 
In the subjects breathing 12% oxygen baseline measurements of all parameters were taken 
again during the initial saline infusion (‘hypoxia alone’ stage).   
Intra-brachial sodium nitrite was then infused at a dose of 7.84µmol/min for 10 minutes 
following which FVV and FBF were assessed (hence nitrite was infused for 20 minutes in 
total).  In the subjects breathing 12% oxygen the face mask was then removed.  Saline was 
then infused for 60 minutes.  Every 15 minutes FVV and FBF were assessed. 
 
Data and Statistical Analysis 
 
All data are expressed as mean±SEM; P values of <0.05 were considered statistically 
significant. Changes in FBF and FVV observed in the study arm were corrected for those in 
the control arm. One-way analysis of variance was carried out for changes in FBFR and 
FVV. 
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5.3 Results 
Subject characteristics  
Grouped baseline characteristics for all patients are shown in Table 5.1.   
Table 5.1 
 
Demographic and Clinical Features 
 
Age (y)  
Sex, M/F 
Body mass index (kg/m
2
)  
Smoking history, (n) 
       Nonsmoker  
       Previous smoker  
       Current smoker  
Serum cholesterol (mmol/L)  
Plasma glucose (mmol/L)  
Serum Creatinine (µmol/l) 
Heart rate 
Blood pressure (mmHg) 
        Systolic 
        Diastolic 
56.2±1.9 
15/2 
26.8±1.1 
 
17 
0 
0 
5.8±0.3 
4.5±0.1 
98.4±2.7 
66.0±3.0 
 
125±3.0 
72.8±1.9 
 
 
 
Venous Tone 
 
Nitrite produced a 34% venodilatation (P=0.01) which was similar in hypoxia and normoxia.  
The venodilation remained significantly greater than baseline even at 15 minutes of saline 
infusion post nitrite in normoxia (P=0.016) and even at 30 minutes there was a trend towards 
significant venodilatation (P=0.057).  In hypoxia the venodilatation persisted in a similar 
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pattern and remained significant until 30 minutes (P=0.009). (Figure 5.1 – Normoxia, Figure 
5.2- Hypoxia ) 
 
Figure 5.1 - Venous Tone 
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Figure 5.1 – Venodilation in ‘normoxia’ 
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Figure 5.2 – Venodilation in ‘hypoxia’ 
 
FBF 
 
Nitrite caused a significant increase in FBFR (P<0.05). (Figure 5.3 – Normoxia, Figure 5.4 - 
Hypoxia)  This increase was still significantly greater than baseline at 30 minutes (P=0.05) in 
normoxia but was no longer significant at 45 minutes.  In hypoxia the pattern of response was 
similar although by 15 minutes of washout FBFR was no longer statistically greater than that 
at baseline.   
 
Saline Alone 
* 
* 
* 
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Figure 5.3 – FBF in ‘normoxia’ 
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Figure 5.4 – FBF in ‘hypoxia’ 
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NO metabolite levels 
 
The levels of nitrite rose in the infused arm during the administration of sodium 
nitrite.(P<0.05)  However, by 15 minutes these levels had dropped 10 fold and were no 
longer significantly different to those in the control arm (Figure 5.5).  There was no 
significant change in the levels of protein bound NO in either arm at any time point (Figure 
5.6). 
  
Figure 5.5 
* 
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Figure 5.6 
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5.4 Discussion 
 
 
We report an enduring effect of nitrite after the levels had dropped 10-fold.  In fact in some 
individuals we actually observed a further increase in vasodilation after termination of the 
nitrite infusion before a gradual return to baseline (data not shown).  In contrast, in previous 
studies in which we have examined the responses to Bradykinin and Carbachol
155, 212
 
venodilation disappeared within five minutes compared to the 30-45 minutes observed with 
nitrite.  Our data would suggest that a potential reservoir may have been created from which 
NO was slowly released leading to the ongoing vasodilation. 
While this study does not investigate the mechanisms underlying this phenomenon it does 
point towards some important possibilities.  Our observations were not explained by an 
increase in circulating protein bound NO metabolites.   
We hypothesise that a proportion of the NO released from nitrite was bound to a component 
of the vessel wall and then released over a period of time.  It is possible that the myoglobin in 
the vascular smooth muscle may serve this function.  In fact, there has been considerable 
recent interest in the role of myoglobin in NO homeostasis.
213, 214
 
In a paradigm similar to that of haemoglobin, we propose that myoglobin may act as a store 
of NO.  NO released from nitrite by deoxymyoglobin could bind to the sulphydryl group of 
the cysteine residue
215
 (position 110) of  human oxyhaemoglobin forming S-NO oxyMb.  
This S-NO oxyMb could act as a stable store of NO with the bound NO being slowly 
released.  Rayner et al have demonstrated in vitro that mixtures containing human ferrous 
oxymyoglobin with NO donors such as S-nitrosoglutathione and S-nitrosocysteine could lead 
to the generation of S-NO oxyMb.  Moreover S-NO oxyMb relaxed preconstricted aortic 
rings in a cyclic GMP dependent manner.
213, 216, 217
 It has been demonstrated that binding of 
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NO to the sulphydryl group of myoglobin is dependent, at least in part, on the oxygen tension 
of the environment.
218
 
We did observe, as in Chapter 2, a greater initial increase in FBFR in hypoxia and a slightly 
quicker return to baseline, however the overall pattern of response was similar in the two 
oxygen environments when comparing the ‘areas under the curve’.  Although we expected 
the response to be modulated by hypoxia, due to an increased level of deoxymyoglobin, this 
was not found in our study.  However an important limitation was the fact although the nitrite 
was infused with the subject breathing 12% oxygen (20 minutes) it was not possible to 
expose the subjects to this degree of hypoxia through the hour long period of saline washout 
as this was beyond the remit of our ethical approval. 
In summary, we have found intra-arterial nitrite to cause a vasodilation that endures for a 
significant length of time after the infusion has ceased, probably due to vascular protein 
binding.  This is both a novel and exciting observation.  While myoglobin could possibly 
mediate this phenomenon further mechanistic studies are needed to elucidate this. 
 
 
This possibility and the role of vascular myoglobin in nitrite reduction was investigated 
further.  The studies and findings are presented in chapter 7. 
 
In order to investigate the effects of intravenous infusion of inorganic nitrite and to inform 
future studies by providing data regarding the safety of its use in this context, a series of 
studies were performed in both normoxia and hypoxia.  These studies are described in the 
next chapter.   
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CHAPTER 6 
 
 
Systemic Effects of Intravenous Sodium Nitrite 
 
 
 
 
Execution 
 
The studies described in this chapter were designed and organised by myself with the normoxic 
studies being executed by myself and the hypoxic studies by Dr Sayqa Arif. Biochemical analysis was 
performed by Dr Phil James and his team at the University of Cardiff, Wales. 
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Abstract 
Aims 
The discovery of nitrite as a source of nitric oxide, particularly in hypoxic and ischemic 
conditions (at least at pharmacological concentrations) has generated great interest amongst 
researchers. When administered intra-arterially under normoxic conditions, nitrite has a 
selective vasodilatory effect on the capacitance bed but during hypoxia marked dilation of 
forearm resistance vessels was also observed. Accordingly, we hypothesised that an 
intravenous infusion of sodium nitrite would cause a significantly greater reduction in blood 
pressure during hypoxia compared to normoxia, in humans.  
Methods  
33 healthy subjects were recruited. An intravenous infusion of sodium nitrite was 
administered at escalating doses (3, 8, 30 and 60µmol/min) during either normoxia or 
hypoxia in random order. Haemodynamic measurements were determined non-invasively 
through the use of a hemodynamic monitoring system (Taskforce®). Aplanation tonometry 
(Sphygmocor®) was used to delineate central aortic blood pressure.  
Results  
To allow for the time-dependent effect of hypoxia all measurements in this group were 
placebo-corrected. During hypoxia systolic blood pressure fell by a mean of 11mmHg (P≤ 
0.05) from baseline at the highest dose of sodium nitrite.  There was a non-significant 
reduction in systolic blood pressure during normoxia of 6mmHg. Heart rate increased in 
association with blood pressure reductions. No significant changes were observed in stroke 
volume, cardiac output or cardiac index with nitrite during either hypoxia or normoxia. In the 
hypoxia group total peripheral resistance mirrored changes in systolic blood pressure. Central 
aortic blood pressure fell in both groups (9 v 13 mmHg in normoxia [P>0.05] v hypoxia 
[P>0.05]) from baseline in both groups. 
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Conclusion  
An acute intravenous infusion of nitrite was safe and well tolerated in healthy volunteers. A 
significant decrease in blood pressure was observed during hypoxia but not during normoxia, 
thus supporting the role of nitrite as a hypoxia-specific vasodilator.  
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6.1 Introduction 
 
Several potential mechanisms by which nitrite may be reduced to NO have been 
demonstrated in animal models, including deoxyhemoglobin, deoxymyoglobin, eNOS, 
xanthine oxidoreductase, acidic disproportionation, and mitochondrial complex IV 
76, 114, 168, 
219-224
. However, one major commonality to all of these mechanisms is that more NO is 
released from nitrite during hypoxic conditions 
225
. Furthermore we were the first to 
demonstrate in man that intra-arterial sodium nitrite infusion only modestly dilated forearm 
resistance vessels but potently dilated capacitance vessels under normoxic conditions in vivo. 
However, under hypoxic conditions it markedly dilated forearm resistance vessels
131
.   
 
In this chapter, we sought to investigate the effect of intravenous sodium nitrite on acute 
haemodynamic parameters in healthy volunteers, during both normoxia and hypoxia. We 
hypothesized the following: 1) While subjects are breathing room air, there would be no 
significant vasodilatation of the resistance vessels as verified by an unchanged arterial blood 
pressure and systemic vascular resistance; 2) When subjects inspire 12% oxygen, rendering 
arterial blood relatively hypoxic a significant reduction in arterial blood pressure and 
systemic vascular resistance would be observed.  
 
6.2 Methods 
 
Subjects  
33 healthy volunteers (20 male and 13 female) were recruited into the study. 18 were 
allocated to protocol A (normoxia) and 15 into protocol B (hypoxia). Participants had no 
history of smoking, were free of known cardiovascular disorders and were not on any regular 
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medication or vitamin supplements. All had a normal cardiovascular examination and 
electrocardiogram. The investigation conforms to the principles outlined in the Declaration of 
Helsinki. The study was approved by the local research ethics committee (ref: 07/Q2707/10 
and 08/H1207/69). All subjects gave written, informed consent. The study was performed at 
the University of Birmingham Clinical Research Block in a quiet vascular laboratory which 
was temperature-controlled at 22 - 24ºC. All subjects had a light breakfast and were requested 
to abstain from alcohol for 24 hours and caffeine-containing drinks for 12 hours before the 
study. 
Subjects were allocated randomly between protocols and A and B of the study. 
 
Measurements 
Cardiac haemodynamic variables were measured noninvasively by transthoracic electrical 
bioimpedance (Taskforce
® 
Monitor
, 
CN Systems, Graz, Austria), as described previously 
226
. 
Blood pressure and heart rate were measured continuously. Impedance cardiography was 
used to determine changes in stroke volume, cardiac output and total peripheral resistance. 
Although absolute values of these parameters measured by the bioimpedance technique differ 
significantly from those measured using the invasive thermodilution technique it has been 
shown to be a valid way of assessing changes in these parameters 
227
. Furthermore, as the 
subject group consisted of healthy volunteers it would have been unjustified to use invasive 
haemodynamic monitoring for the sole purpose of this study.  
The haemodynamic data were used for calculation of BRS using the sequence method 
228
. 
The algorithm searches for episodes of spontaneous activation of the baroreceptor reflex. 
Episodes of baroreceptor reflex activation/inactivation  are defined when blood pressure 
rises/falls for at least 1 mm Hg for at least four consecutive heartbeats and when, 
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simultaneously, decrements/increments of RR-interval of at least 4 ms/beat, respectively, 
occur. Linear regressions of increments/decrements in systolic blood pressure and 
increments/decrements in RR-interval were computed. Only episodes with correlation 
coefficients of greater than 0.8 were selected, and from all regressions, a mean slope of 
baroreceptor sensitivity was calculated for each steady state period. Spectral analysis of RR-
interval (RRI) to determine HRV was performed  as described elsewhere 
229
. Parameters of 
low frequency (LF) and high frequency (HF) components were expressed as normalised units 
(nu). 
The technique of aplanation tonometry using SphygmoCor® (AtCor Medical, 
Gloucestershire, UK) was used to estimate central aortic pressure non-invasively, and has 
been described elsewhere 
230
. Pulse wave contour analysis was performed by taking a 
recording at the radial artery. Arterial waveforms were recorded non-invasively over 10 
seconds using a high-fidelity hand-held tonometer. The radial pressure wave was calibrated 
to brachial blood pressure (Taskforce
®
).  The central aortic pressure waveform was calculated 
using a validated generalized transfer function. 
 
Study medication 
Sodium Nitrite was obtained from Martindale Pharmaceuticals UK (Brentwood, United 
Kingdom). It was diluted to the required concentration using 0.9% sodium chloride solution. 
An intravenous infusion of sodium nitrite at a rate of 1ml/min was used as placebo. 
 
Study Protocols 
 
Protocol A - normoxia 
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Subjects were placed in a semi recumbent position on a hospital bed. This position was used 
as it allowed 12% oxygen to be administered to participants entered into protocol B. An 
intravenous cannula (Venflon, 20 Gauge) was inserted into a vein in each antecubital fossae. 
Blood was drawn and sent for a full blood count and biochemical profile (plasma urea, 
electrolytes, creatinine, glucose and cholesterol levels). Each subject underwent placement of 
a finger cuff for continuous blood pressure recording, an upper arm cuff for the oscillating 
blood pressure measurement and ECG and band electrodes on the trunk for cardiography.  
 
Following 10 minutes of rest, an intravenous infusion of 0.9% sodium chloride (’normal 
saline’) was started for 20 minutes. 10 minutes into the infusion, haemodynamic variables 
were recorded using the Taskforce
®
 over a 10-minute period. During this recording period 
three 10-second measurements of pulse wave analysis at the radial artery were performed, 
using the Sphygmocor technique. A mean of the three recordings was calculated and used for 
subsequent data analysis. The above measurements were repeated during intravenous 
infusion of sodium nitrite at 3 escalating doses of 8µmol/min, 30µmol/min and 60µmol/min. 
The starting dose of 8µmol/min was used during normoxia in light of our findings in chapter 
2, where a dose of 7.84µmol/min was well-tolerated and produced significant changes in the 
forearm vasculature 
131
.   
 
Protocol B - hypoxia 
Subjects were prepared as for protocol A. Oxygen saturation levels were monitored 
continuously with pulse oximetry (Nellcor N-180, Nellcor, Pleasanton, California). Hypoxia 
was induced by subjects breathing in 12% oxygen via a facemask connected to a two-way 
valve. Target oxygen saturation as measured by pulse oximetry was 83% - 88% (estimated 
pO2 of 47.5 – 55 mmHg, based on Severinghaus’ equation). The hypoxia protocol was 
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executed in two stages, at least 24 hours apart. Once patients reached target oxygen 
saturations the saline infusion was commenced. Initially saline was infused for 1 hour 15 
minutes in total. On the second visit at a similar time in the day, three concentrations of 
sodium nitrite (3µmol/min, 30µmol/min and 60µmol/min) were then infused. As a 
precaution, a lower starting dose of sodium nitrite was used in this Group due to the 
anticipated effect on systemic blood pressure during hypoxia. Each infusion lasted 25 
minutes each resulting in a total infusion time of 1 hour 15 minutes. As described in protocol 
A, cardiac haemodynamic measurements were recorded 10 minutes into each infusion. 
Autonomic parameters were recorded during the last 5 minutes of the 25-minute infusion. 
Hence, both the saline and nitrite arms of this protocol lasted for the same duration to allow 
for the time-dependent effect of hypoxia on our measurements.  
 
Data and Statistical Analysis 
Data was analyzed using SPSS version 15.0 software (SPSS Inc., Chicago, USA). Study 
results that are normally distributed are expressed as mean ± standard deviation (mean±SD) 
and non-normally distributed data are presented as median plus interquartile range (IQR). 
Probability values of <0.05 were considered statistically significant. For normally distributed 
data repeated measures ANOVA was used to analyze the data within groups and between 
group data was analyzed using ANCOVA. The non-parametric equivalents used were 
Friedman’s tests with Wilcoxon-Rank Sign Test for post hoc analysis and the Mann-Whitney 
U test for between-groups analysis. The Bonferroni correction was applied where necessary. 
The authors had full access to the data and took responsibility for its integrity.  
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6.3 Results 
 
Baseline Characteristics 
 
There were no significant differences in the general characteristics of the study subjects in the 
two protocols (Table 6.1). 
 
 
 
 Hypoxia 
n=15 
Normoxia 
n=18 
P value 
    
Age (years) 31±11 32±9 0.72 
Gender (n)              ♂ 10 / ♀ 5               ♂ 10 / ♀ 8           
Mean weight (kg) 72±18 69±11 0.35 
Body mass index 
(kg/m
2
) 
24±5 24±3 0.98 
Haemoglobin (g/dL) 13.8±0.8 13.8±1.1 0.65 
Creatinine (µmol/l) 85±15 90±17 0.94 
Cholesterol (mmol/l) 4.6±1.1 4.5±0.8 0.25 
Glucose (mmol/l) 4.6±0.6 4.5±0.7 0.64 
 
Table 6.1  
Baseline characteristics of the study subjects 
(Apart from gender all values are expressed as mean±standard deviation) 
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Cardiac haemodynamic data 
 
Blood pressure 
There was no significant reduction in systolic blood pressure with nitrite infusion at any 
concentration during normoxia with a mean BP reduction from baseline of 120±13mmHg to 
114±22mmHg  at the 60µmol/min dose of sodium nitrite (P>0.05). During hypoxia, however 
there was a significant mean reduction in blood pressure of 11mmHg from 123±19mmHg to 
112±15mmHg at the 60µmol/min dose from baseline (P<0.05). Sodium nitrite was infused at 
the 60µmol/min dose in 7 and 6 subjects in the hypoxia and normoxia groups respectively. 
The mean reduction in blood pressure between the two groups was not significantly different 
(P>0.05). 
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Fig. 6.1b)  
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Systolic blood pressure during a)normoxia ,b)hypoxia and c)both at 60 micromol/min dose. 
N=6 and 7 at the 60 micromol/min dose during normoxia and hypoxia respectively.  
 
Heart rate 
An increase in heart rate was observed in both groups. In normoxia, a reduction in systolic 
blood pressure of 6mmHg (at the 60µmol/min dose) was associated with an increase in heart 
rate of 8bpm (61±4 to 69±9bpm, P<0.05). During hypoxia, the heart rate at this dose 
increased by 13bpm (73±15 to 86±17bpm, P<0.05) in association with a mean reduction in 
blood pressure of 11mmHg (fig. 6.2). 
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Fig. 6.2 Heart rate in response to an infusion of sodium nitrite during a)normoxia and 
b)hypoxia. N=6 and 7 at the 60 micromol/min dose during normoxia and hypoxia 
respectively. 
 
Stroke volume, cardiac output, cardiac index, total peripheral resistance, total peripheral 
resistance index  
 
There was no significant change in SV, CO or CI in either group during nitrite infusion 
compared to placebo (Table 6.2). TPR and TPR index mirrored changes in systolic blood 
pressure (fig. 6.3). The reduction in TPR and TPRI was significant in the hypoxia group at 
the 60µmol/min dose (P<0.05) but not in the normoxia group (P>0.05).  However the change 
in TPR and TPRI was not significantly different between the normoxia and hypoxia groups. 
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 normoxia 
n=6 
P-value*  hypoxia 
n=7 
P-value* 
 
     
SV (ml/min) 82.6±16.4 0.14 75.5±22.3 0.1 
CO (L/min) 5.7±1.7 0.93 6.3±1.1 0.16 
CI (l/[min*m²]) 3.2±0.9 0.79 3.4±0.6 0.14 
TPR (dyne*s/cm^5) 1154±265 0.25 1069±239 0.05 
TPRI (dyne*s*m²/cm^5) 2064±587 0.29 1993±564 0.05 
* compared to baseline 
 
Table 6.2.  
Cardiac haemodynamic parameters following an infusion of sodium nitrite at the 60µmol/min 
dose. 
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Fig. 6.3b) 
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Fig. 6.3  
Changes in TPR mirrored changes in systolic blood pressure during a)normoxia (n=6) and 
b)hypoxia (n=7). Data shown is for baseline and sodium nitrite at the 60µmol/min dose. 
 
Autonomic data 
 
In a sub-set of subjects in the hypoxia group (n=5) baroreceptor sensitivity and heart rate 
variability were studied (fig. 6.4). Data are presented as median (IQR). During hypoxia alone 
both baroreceptor sensitivity and heart rate variability remained unchanged (data not shown). 
Following intravenous infusion of 60µmol/min nitrite under hypoxic conditions, BRS was 
unchanged (median of   14.7 [11.5 – 34.8]) ms/mmHg baseline to a median of 14.1 (5.6 – 
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25.1) ms/mmHg during 60µmol/min nitrite infusion (P>0.05). However, HFnuRRI decreased 
significantly from 63.3% (50.8 – 71.7) to 39.8% (19.3 – 47.2, P<0.05). During nitrite 
infusion  LFnuRRI increased by 36.7% (28.3 – 49.1) to 60.2% (52.8 – 80.6, P>0.05).  
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Fig. 6.4b) 
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Fig. 6.4 Changes in autonomic parameters during hypoxia following an infusion of sodium 
nitrite 
a)baroreceptor sensitivity, b)HRV - HFnuRRI and c) HRV – LFnuRRI. Data shown is 
expressed as median (IQR). 
 
Central aortic pressures and aortic augmentation index 
 
There was a trend towards reduction in central aortic pressure during hypoxia and normoxia 
at the 60µmol/min dose (Table 6.3). Data is presented as median (IQR). The central (aortic) 
systolic blood pressure decreased by 9mmHg from 104(95-112)mmHg to 95(90-98)mmHg at 
the 60µmol/min during normoxia, compared to baseline (P>0.05). During hypoxia there was 
a reduction of 13mmHg from 102(97-122)mmHg to 89(86-104)mmHg, compared to baseline 
(P>0.05).  
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 baseline nitrite# P-value*  
Normoxia (n=8)    
pSBP (mmHg) 120(113 – 128) 114 (108 – 116) 0.12 
cSBP (mmHg) 104 (95 – 112) 95 (90 – 98) 0.06 
Hypoxia (n=5) 
 
   
pSBP (mmHg) 117 (113 – 138) 105 (100 – 128) 0.08 
cSBP (mmHg) 102 (97 – 122) 89 (104 – 86) 0.08 
*compared to baseline; Abbreviations used: peripheral systolic blood pressure (pSBP); 
central systolic blood pressure (cSBP). 
# Data shown is for  nitrite at the 60µmol/min dose. 
 
 
Table 6.3. Changes in cardiac haemodynamics as measured by applanation tonometry. Data 
shown is expressed as median (IQR).  
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6.4 Discussion 
 
This study demonstrated that under normoxic conditions, an intravenous infusion of sodium 
nitrite up to a dose of 60µmol/min did not significantly alter cardiac haemodynamic 
parameters, with the exception of heart rate which increased by 8bpm  equating to a 13% 
increase from baseline (P<0.05). There was a 5% reduction in systolic blood pressure but this 
did not reach statistical significance. In contrast, during hypoxic conditions, 60µmol/min of 
intravenous sodium nitrite significantly reduced systolic blood pressure by 9% (P<0.05). 
Furthermore, both TPR and TPRI decreased significantly in the hypoxia group thus in 
keeping with a reduction in systemic blood pressure.  
 
Central aortic pressure as measured by applanation tonometry decreased non-significantly 
from baseline in both normoxic and hypoxic groups. However, there was a greater reduction 
associated with hypoxia of 13mmHg than during normoxia (9mmHg). The findings in 
hypoxia did not reach significance but this could be explained by missing data due to a 
measurement error resulting in values for only 5 subjects in the hypoxia group and hence 
under-powering of data in this group. 
 
Autonomic measurements appropriately mirrored the changes in blood pressure with a 
resultant tachycardia. Vagal tone decreased as evidenced by a decreased in HFnuRRI and 
sympathetic tone increased reflecting the increase in LFnuRRI during hypoxia. It should 
however be noted as a limitation that, although changes in HFnuRRI and LFnuRRI have 
generally been interpreted as reflecting changes in vagal and sympathetic tone respectively, 
neither of these measures has a high degree of specificity. 
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During hypoxia, the measurements were corrected for the time dependent effect of hypoxia. 
Furthermore, an acute intravenous infusion of sodium nitrite was well tolerated and safe in 
both the hypoxia and normoxia group. No adverse events were seen. To our knowledge this is 
the first study in humans investigating the acute effect of an intravenous infusion of nitrite on 
cardiac haemodynamic parameters. 
 
Following renewed interest in nitrite, numerous mechanisms for nitrite reduction to bioactive 
NO have been investigated. The potential of nitrite as a source of NO during hypoxia was 
first demonstrated in 1937, and then later in 1981 when Doyle et al. reported that nitrite reacts 
with deoxyhemoglobin (in the presence of protons) to produce methemoglobin and NO 
231
. 
Hemoglobin deoxygenation is closely associated with the physiological oxygen gradient, 
advocating the role of nitrite as an effector of hypoxic vasodilation.  This was demonstrated 
in humans by Cosby et al who demonstrated that nitrite at near physiological and supra 
physiological concentrations was associated with vasodilation with deoxyhemoglobin as an 
important nitrite reductase 
184
. It has been suggested that nitrite reduction by non-enzymatic 
acid disproportionation and enzyme reduction by XOR both require low oxygen tensions 
further lending support to nitrite as an effector of hypoxic vasodilation 
114
. More recently 
deoxymyoglobin has been reported to be an oxygen-independent nitrite reductase 
76, 232
. We 
have demonstrated that in isolated mouse aortic rings from wild-type and myoglobin 
knockout mice, there is a markedly reduced (>50%) reduction in vascular reactivity in the 
knockout mice compared to the wild types during hypoxia (unpublished data). This has been 
confirmed in vivo in mice and in isolated mice heart preparations where myoglobin not only 
serves as a functional nitrite reductase, but regulates responses to cellular hypoxia and 
reoxygenation 
116
. It has been proposed that these numerous mechanism may allow for 
generation of bioactive NO in vivo across the physiological oxygen gradient 
85
.   
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Although, the present study has not addressed the mechanisms related to nitrite reduction it 
adds important new information into the role of nitrite during hypoxia in humans. Significant 
blood pressure reductions were seen in the hypoxia group at pharmacological doses of nitrite. 
These results corroborate our earlier findings that under hypoxic conditions, nitrite is an 
arteriolar as well as venous dilator strengthening the case for nitrite as an effector of hypoxic 
vasodilation. 
131
 
  
6.5 Limitations 
The limitations of this study include the small numbers of subjects used. For greater accuracy 
and reliability invasive methods of measuring cardiac haemodynamics would ideally have 
been utilised. Sodium nitrite as a vasodilator, and more importantly a selective venodilator, 
has the potential to reduce cardiac filling pressures with an increase in stroke volume without 
hypotension. Recently, a study in rats showed that intravenous sodium nitrite significantly 
decreased pulmonary and systemic arterial pressure and increased cardiac output 
233
. This 
information can only be reliably obtained by invasive measurements. However, the use of 
such investigative tools in healthy volunteers would be deemed unjustified for the purpose of 
research alone. 
 
We recognize that the main potential adverse effect of sodium nitrite is the development of 
methaemoglobinaemia 
233
. In this study we did not measure methaemoglobin levels. However 
we investigated the cardiac hemodynamic effects of intravenous sodium nitrite in patients 
(n=16) with advanced congestive heart failure (Chapter 3). An infusion of sodium nitrite of 
50µg/kg/min was associated with an increase in methemoglobin levels, which is well within 
safe levels, of 0.3±0.1% to 1.1±0.5%.  Future studies will need to measure methaemoglobin 
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levels especially after administration of longer infusions of sodium nitrite to ensure these 
results are repeated.  
 
We have demonstrated that an intravenous infusion of sodium nitrite is safe and well 
tolerated in humans. When administered systemically, nitrite retains venoselectivity during 
normoxia with arterial hypotension observed during hypoxia. Furthermore, intravenous 
sodium nitrite has been associated with a favourable cardiac hemodynamic response in 
animal models 
233, 234
. This coupled with its lack of development of tolerance 
46
 makes nitrite 
an attractive potential therapeutic option for patients with acutely decompensated heart 
failure to ease cardiac congestion and regain symptomatic control. However, its role in such a 
group of patients needs to be investigated further. 
 
6.6 Conclusion 
A short intravenous infusion of sodium nitrite was safe and well tolerated by healthy subjects 
with a significant reduction in blood pressure during hypoxia thus, supporting the role of 
nitrite as an effector of hypoxic vasodilation. Further studies need to be performed to explore 
the role of sodium nitrite as a potential therapeutic option for heart failure. 
 
Finally, in order to investigate the role of vascular myoglobin in nitrite reduction and building 
on the results presented in chapter 5 we conducted a series of experiments investigating the 
effects of nitrite upon vascular ring relaxation of vessels taken from wild type and myoglobin 
knock-put mice. These studies and their findings are presented in chapter 7. 
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Chapter 7 
 
The Role Of Myoglobin In Vasodilatation By Nitrite  
 
 
The data in this chapter has been published in the journal “Cardiovascular Research”: 
 
 Julian O.M. Ormerod#, Houman Ashrafian#, Abdul Maher#, Sayqa Arif, Violetta Steeples, 
Gustav V.R. Born, Stuart Egginton, Martin Feelisch, Hugh Watkins, Michael P. Frenneaux. 
The Role of Vascular Myoglobin in Nitrite mediated blood vessel relaxation. Cardiovasc 
Res. 2011 Feb 15;89(3):560-5. Epub 2010 Oct 1. 
 
 
Execution: 
 
The studies in this chapter were performed in collaboration with Dr Jules Ormerod – The initial 
washout studies were designed and performed by myself.  Myoglobin knockout mice were obtained 
by me. The transfection and restitution studies in this chapter were performed by Dr Ormerod. 
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7.1. Introduction 
Myoglobin (Mb) is widely expressed in the cytoplasm of vertebrate muscle cells, both 
skeletal and cardiac, with a much lower or absent expression in smooth muscle 
235
. The 
tertiary structure of the globular protein was derived using x-ray crystallography in the 1950s 
236
. Myoglobin consists of a densely packed, 153 amino acid polypeptide chain, with an iron-
porphyrin heme group that is identical to that of Hb. This feature allows Mb to reversibly 
bind and release O2, though the saturation kinetics are different (due to differences in the 
globular protein as well as the lack of quaternary structure) and act as a short-term store of 
oxygen in exercising muscle. The heme of myoglobin achieves 50% saturation at intracellular 
levels of O2 as low as 2.4 mmHg 
237
 and so is fully saturated under normal conditions. 
Exercising muscle can, however, reach near anoxia at very high workloads. Intriguingly, 
despite this important physiological role, the myoglobin knockout mouse is remarkably 
healthy, with tissue oxygenation maintained primarily by an increased capillary density 
238, 
239
. 
 
It is believed that myoglobin subserves an intracellular process known as “facilitated 
diffusion” of oxygen. Deoxygenated Mb binds O2 at the cell membrane and diffuses through 
the cytoplasm to the mitochondria, where it releases O2 to the respiratory chain. The 
deoxygenated Mb then diffuses back down its concentration gradient to the membrane to 
repeat the cycle 
240
. Experimental evidence for this phenomenon is far from unambiguous, 
with model calculations both supporting and refuting myoglobin’s contribution to cellular O2 
flux
241
.  
 
The chemistry of nitrite activation in vivo remains uncertain
61
 . Several (non-exclusive) 
bioconvertors have been identified including: pH-dependent enzyme-independent nitrite 
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reduction
242
 ; microsomal cytochrome P-450 (Kozlov, Staniek, & Nohl 1999; Li et al. 2006); 
xanthine oxidase 
61
; aldehyde oxidase (ALDH2) 
61
; neuroglobin 
243
; hemoglobin 
49, 50, 52, 53, 
244
; and myoglobin 
57
. It is uncertain which of these, alone or in combination, contributes to 
the in vivo conversion of endogenous and exogenous nitrite. In particular, the role of heme 
moieties, e.g. hemoglobin, in nitrite metabolism, is still uncertain 
245
. We devised 
experiments to test the hypothesis that vascular myoglobin, like cardiac myoglobin 
246
, can 
act as a bioconvertor for exogenous nitrite. 
 
We have observed a prolonged vasodilating action of nitrite, which persisted for 45 minutes 
after the infusion of nitrite was stopped. Intriguingly, this vasodilatation was only observed in 
the infused arm, even though plasma nitrite levels rapidly equilibrated between the two arms. 
We hypothesized that an intrinsic vascular wall protein was therefore responsible. This 
hypothesis was supported by work from the Zweier lab indicating the same 
61, 245
. Their 
experiments also implicated an intrinsic vascular wall protein, and narrowed the search to 
heme-proteins by inhibition of such using carbon monoxide gas. Accordingly, we undertook 
experiments to investigate directly the role of myoglobin in nitrite-induced vasorelaxation. 
 
7.1.1 Hypothesis 
Ablation or inhibition of myoglobin, genetically or with carbon monoxide gas, will reduce 
the vasodilating response of aortic tissue to sodium nitrite 
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7.2. Methods 
 
7.2.1 Animals  
Male NMRI and myo
-/-
 mice were used at 6-7 weeks of age (26-32g in weight). We housed 
all animals under standard lighting parameters and provided food and water ad libitum. 
Animals were killed by cervical dislocation as approved under Schedule 1 of the Animals 
(Scientific Procedures) Act 1986. Aorta from arch to diaphragm was quickly removed en 
bloc, and immediately plunged into ice-cold oxygenated Krebs solution. Aorta was cleaned of 
all adherent fat and adventitia, and cut into four 2 mm rings. These were mounted in organ 
baths on a wire myograph (Danish Myo Technology). 
 
7.2.2. Mouse aortic ring myography  
Aortic myography was done according to standard procedures.  Pretension force was 20 mN. 
Preconstriction was produced using 50 mM KCl or x mM phenylephrine. Myography wells 
were open to the air and bubbled with 95% nitrogen- 5% CO2 (with and without carbon 
monoxide, CO), or with 95% O2 - 5% CO2. Buffer was allowed to reach steady state, which 
using this equipment produced an oxygen tension of 83 ± 2.5 mmHg (11 kPa) for the low 
oxygen gases, and 158 ± 2.4 mmHg (22 kPa) for the high oxygen mix. The lower level, 
which was used for the majority of experiments, was chosen in order to approximate to in 
vivo intravascular conditions, as it is between the average oxygen tension of arteries (90 
mmHg) and veins (40 mmHg) 
247
. This level was stable over time. 
 
7.2.3. Generation of replication-defective adenoviruses  
Both Ad5-Myo-GFP and Ad5-GFP (control virus) were generated using the AdEasy XL 
Adenoviral vector system (Stratagene). Human wild-type myoglobin cDNA was cloned into 
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the pShuttle-IRES-hrGFP-1 vector (Stratagene), allowing co-expression of GFP with 
myoglobin (a stop codon was introduced to prevent fusion of the FLAG tag). The vector was 
linearized by PmeI digestion and recombined with the pAdEasy-1 (viral backbone vector) in 
BJ5183 Escherichia coli. The recombined adenoviral constructs were transfected into DH10 
E. coli to allow higher plasmid yields. After confirmation of recombination by BstXI and 
Pac-1 restriction digestion and sequencing, Pac1 linearized recombinant Ad plasmids were 
then transfected into AD293 cells (Stratagene) using oligofectamine (Invitrogen). AD293 
cells were scraped from cell culture vessels and lysed by 4 freeze-thaw vortex cycles. Lysates 
containing recombinant adenoviruses used to infect further AD293 cells for amplification. 
The viruses were purified by caesium chloride gradient ultracentrifugation. The viral titre was 
estimated by infecting HEK293 cells (not expressing capsid proteins) and counting GFP 
expressing cells. 
 
7.2.4. End-point PCR and western blotting  
Aortas from myo
-/-
 and wild-type control mice were harvested as before and flash frozen in 
liquid nitrogen. RNA and protein were extracted using TriReagent (Sigma). cDNA was 
transcribed from purified RNA using a standard kit (Applied Biosystems) and 40 cycles of 
PCR were performed. The protein fraction was purified and used for western blotting.  
 
7.2.5. Measurement of cGMP accumulation 
Fresh aortas were harvested as before. Tissue was exposed to 10 mM nitrite in Krebs-
Hensleit buffer at 37 ºC for 15 minutes, with and without the NO scavenger carboxy-PTIO. A 
phosphodiesterase inhibitor cocktail was used in the buffer, as in previous work in the 
Feelisch group 
248
. Samples were flash frozen in liquid nitrogen and homogenised by 
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crushing in a frozen mortar and pestle, as the blade homogeniser was ineffective for aortic 
tissue. cGMP was measured using a commercial ELISA kit (Amersham Biotech, UK). 
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7.3. Results 
 
7.3.1. Myoglobin is present in the normal mouse aorta 
Myoglobin is present at the mRNA (figure 7.1a) and protein (figure 7.1b) level. 
 
7.3.2. Nitrite-induced vascular relaxation is oxygen-dependent 
In preliminary experiments in C57bl6 mice (a commonly-used laboratory mouse), reducing 
the buffer oxygen tension increased vasorelaxation to 9 mM sodium nitrite (n = 6, P < 0.05 
by two-tailed t-test) (figure 7.2). This confirms previous observations. 
 
7.3.3. Deficiency or inhibition of myoglobin in mouse aorta diminishes vasorelaxation to 
nitrite 
Acute vasorelaxation induced by sodium nitrite was assessed during exposure to 95% N2/5% 
CO2 and then to 20% CO/ 75% N2/ 5% CO2. The level of CO was chosen to inhibit only 
heme-proteins, as previously described
23
, and did not in itself cause vasorelaxation. 
Preliminary experiments with a fixed dose of sodium nitrite (9 mM) showed a differential 
response to carbon monoxide. Bubbling with the 20% CO mix inhibited relaxation in the 
wild-type (NMRI) group (n = 5, P < 0.05 by ANOVA), but potentiated relaxation in the myo
-
/-
 mouse vessels (n = 4, P < 0.01 by ANOVA). Further experiments assessed the contribution 
of myoglobin at several increasing doses of sodium nitrite. CO inhibited nitrite-induced 
vasorelaxation in the murine wild-type aortae (n = 5, P < 0.001 by two-way ANOVA) (figure 
7.4a) suggesting that an intrinsic vascular heme moiety significantly contributes to vascular 
nitrite bioconversion. The effect of 50 μM oxypurinol (an inhibitor of xanthine oxidase) and 
50 nM raloxifene (an inhibitor of aldehyde dehydrogenase) is shown for comparison. To 
assess whether myoglobin was this heme moiety, myo
-/-
 mice
24
 were compared to wild-type 
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controls. Overall response to nitrite was markedly reduced in myo
-/-
 rings (figure 7.4b) (n = 
5, P < 0.001 by two-way ANOVA), implying that myoglobin significantly contributes to 
vascular nitrite bioconversion. In contrast to wild-type aortae, CO did not inhibit 
vasorelaxation in myo
-/-
 rings (figure 7.4b). 
 
7.3.4. Restitution of myoglobin recapitulates wild-type response to carbon monoxide 
To confirm the role of myoglobin as a nitrite bioconvertor and to exclude the possibility that 
the changes noted in the myo
-/-
 mice were artefactual adaptations to gene manipulation, we 
investigated the effect of restoring myoglobin in myo
-/-
 mouse vessels. Transduction of 
myoglobin augmented the baseline response to nitrite from 28.6 ± 6.5% to 60.7 ± 7.6% (P = 
0.024 by ANOVA), compared to control virus-treated rings (figure 7.5). The pattern of 
response to CO was similar. Thus, treatment with control virus did not change the effect of 
CO (from 28.6 ± 6.5% to 31.6 ± 7.0%). Crucially, viral transduction of myoglobin reinstated 
the inhibition of nitrite relaxation by CO seen in wild-type mice (from 60.7 ± 7.6% to 25.8 ± 
3.7%, P = 0.014 by ANOVA). The concentration of nitrite (~EC90 at 9 mM) used in this 
study was chosen to facilitate accurate determination of the vasorelaxing effect of nitrite with 
other pathways saturated. Western blotting confirmed the presence of myoglobin in aortic 
tissue treated with adMYO (figure 7.1b). 
 
7.3.5. Relaxation to sodium nitroprusside is increased by carbon monoxide in both wild-
type and myo
-/- 
rings 
Sodium nitroprusside (SNP) was used to assess the effect of CO on vasorelaxation by a 
nitrite-independent NO donor. Importantly, myo
-/-
 aortic rings retained their response to NO 
(i.e., the extent of vasorelaxation to a fixed concentration of SNP (0.1 µM) was comparable 
in tissues from wt and myo
-/-
 mice) and relaxation was increased from 37.7 ± 3.5% to 43.7 ± 
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4.2% by the addition of CO (P = 0.032 by ANOVA). In wild-type mice, relaxation was 
increased from 42.3 ± 4.7% to 58.7 ± 6.0% (P = 0.029 by ANOVA) (figure 7.6). The 
difference in magnitude of effect of CO is consistent with greater scavenging of NO by 
myoglobin in the wild-type mouse. 
 
7.3.6. Xanthine oxidase and aldehyde dehydrogenase also exhibit nitrite reductase activity 
50 μM oxypurinol caused a 32% inhibition of vasorelaxation (from 21.3 ± 0.4% to 14.4 ± 
1.4%, P < 0.05 by ANOVA) whereas 50 nM raloxifene produced a 32% inhibition (from 21.3 
± 0.4% to 14.3 ± 0.5%, P < 0.05 by ANOVA). The two agents in combination inhibited 
nitrite-induced vasodilation by 60% (from 21.3 ± 0.4% to 8.5 ± 1.1%, P < 0.001 by ANOVA, 
n = 4 for each group) (figure 7.7). Preincubation time of vascular rings with inhibitors was 
five minutes with each agent separately or together; optimal concentrations of inhibitors used 
were determined in preliminary experiments. 
 
7.3.7. Nitrite vasodilates through release of nitric oxide 
In the presence of a phosphodiesterase inhibitor cocktail, exposure of vascular tissue to 9mM 
nitrite for 15 minutes caused accumulation of cGMP, which was lower in myo
-/-
 tissue than in 
wild-type and abolished by preincubation with the NO-scavenger, carboxy-PTIO (figure 
7.8a). Moreover, relaxation of aortic rings by nitrite was completely abolished by 
preincubation with 20 µM oxygenated hemoglobin (oxyHb) or by the addition of 10 µM 
ODQ to the organ bath, suggesting the effects of nitrite are mediated by the stimulation of 
soluble guanylyl cyclase by free NO (figure 7.8b). 
 
 
7.3.8. Prolonged vasodilatation to nitrite is partially myoglobin-dependent 
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Aortic ring studies were also performed to investigate the initially-recorded phenomenon of 
prolonged vasodilatation, first seen in human studies.  Ten-minute exposure to 18 mM nitrite 
induced a characteristic persistent vasorelaxation in aortic rings a) Typical traces for nitrite-
induced relaxation in NMRI (grey) and myo
-/-
 (black) aortic rings b) Latency time, T(0), is 
shorter in myo
-/-
 compared to wild-type controls, (n = 4 for each, P < 0.05 by two-tailed t-test) 
(figure 7.9). This implies that the phenomenon relies in part upon the presence of myoglobin. 
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7.4. Discussion 
The main findings of the in vitro study are that: a) vascular bioconversion of exogenous 
nitrite is sensitive to CO, and therefore is likely to depend upon a heme-protein; b) in 
contrast, when CO is used in rings from myoglobin-deleted mice vasorelaxation is unchanged 
or increased; this implies that the contribution of remaining heme-proteins (other than 
myoglobin) is net NO scavenging; c) deletion of myoglobin substantially diminishes 
exogenous nitrite-mediated vasorelaxation; indicating that myoglobin is a major bioconvertor 
of exogenous nitrite in aortic rings; d) restitution of myoglobin to myo
-/-
 mouse aortas results 
in increased vasodilation; and the wild-type pattern of response to CO (i.e. inhibition of 
vasodilation) is restored; e) further studies using inhibitors imply that the other major 
bioconvertors in this model are non-heme enzymes, including xanthine oxidase and aldehyde 
dehydrogenase. 
 
Carbon monoxide, an inhibitor of heme-proteins, had differing effects on wild-type and 
myoglobin-deleted aortic rings; this is only explicable by the presence of myoglobin in 
murine vasculature. This is confirmed by the demonstration of myoglobin at the transcript 
and protein level. The results summarised in a) to d) above support the hypothesis that 
myoglobin is a significant bioconvertor of exogenous nitrite. 
 
7.4.1. Limitations 
A major controversy that cannot be resolved by this system is the relative contribution of 
haemoglobin to nitrite-induced vasodilatation, either in physiology or therapeutics. Stamler 
and others have proposed that SNO-Hb, created by nitrite, can provide a source of NO-like 
bioactivity, without need for free NO. Certainly, these results (particularly those using the 
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scavenger carboxy-PTIO) imply that free NO is important, but the lack of either haemoglobin 
or intact erythrocytes in the experimental setup means that this work can shed no light on the 
controversy. The oxygen tension in these studies was chosen to represent low arterial levels, 
and it was assumed that tissue levels would quickly equilibrate with the surrounding buffer. It 
cannot be excluded that certain areas of aortic tissue, or subcellular compartments, experience 
much lower oxygen levels. This would explain the apparent discrepancy between 
biochemical studies of myoglobin’s nitrite reductase activity and the present organ bath 
study. It is of course similarly possible that such effects would be present in vivo. 
The experiments were designed to focus on smooth muscle myoglobin, and so the majority of 
aortic rings had the endothelium removed. Also, in this model the relative contribution of 
myoglobin is only clear at higher levels of nitrite than are found in normal human physiology. 
However, nitrite levels recorded in humans vary over more than an order of magnitude; for 
example, micromolar levels a have been measured in altitude-adapted individuals (Himalayan 
study). Levels of nitrite recorded in aortic tissue are strikingly higher than in plasma (>20 
M). Oxygen tension in resting muscle is approximately 24 mmHg, and working muscle 
exhibits even greater hypoxia (8 mmHg) 
249
, which together mean that myoglobin is likely to 
participate in vasodilatation during physiological circumstances, and not just in pathology 
(anoxia, extreme acidosis) as previously hypothesised. 
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7.5. Conclusions 
 
Nitrite relaxes aortic rings at near physiological levels of oxygen, but low pharmacological 
levels of nitrite. Nitrite may be present in much higher quantities in certain tissues. 
Vasorelaxation proceeds through the liberation of NO, as it may be blocked by G-protein 
inhibitors or NO-scavengers, and myoglobin is important in this process. Xanthine oxidase 
and ALDH2 contribute to the remainder of the vasorelaxing effect. A summary of this model 
is given in figure 7.10. Prolonged latency is a hallmark of nitrite-induced vascular relaxation; 
it is also partially myoglobin-dependent.  
164 
 
7.6. Figures 
 
Figure 7.1. 
 
 
 
a) 
 
b) 
 
 
Figure 7.1: Myoglobin is present in the normal mouse vasculature 
a) End-point PCR showing presence of myoglobin mRNA in aortic and cardiac tissue from a 
wild-type (NMRI) mouse, and absence in myo
-/-
 tissue b) Western blot showing presence of 
myoglobin in aortic and cardiac tissue from a wild-type (NMRI) mouse, and absence in myo
-/-
 
tissue. Myoglobin is restored in myo
-/-
 tissue using a recombinant adenovirus (AdMYO) 
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Figure 7.2. 
 
 
 
 
 
 
 
Figure 7.2: Nitrite relaxes mouse aorta in an oxygen-dependent manner 
Confirming previous work, lowering the buffer oxygen tension from 158 mmHg to 84mmHg 
increased relaxation to 9 mM sodium nitrite from 26.0 ± 4.5 to 33.1 ± 5.1 in C57bl6 mouse 
aortas, *P< 0.05 
166 
 
Figure 7.3. 
a) 
 
b) 
 
 
 
Figure 7.3: Exposure to carbon monoxide causes a differential response in wild-type aortas 
compared to myoglobin knockout 
a) Relaxation to 9 mM sodium nitrite is inhibited by exposure to 20% CO gas in NMRI 
mouse aorta, whereas b) relaxation to 9mM sodium nitrite is lower overall in myo
-/-
 
aorta compared to NMRI and is potentiated by CO gas; the effect of reducing oxygen 
tension is similar to that in C57bl6 aortas (figure 3.2) for both. 
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Figure 7.4. 
a) 
 
 
b) 
 
Figure 7.4: Vasorelaxation to nitrite is reduced by both inhibition of myoglobin with 
CO and ablation by genetic knockout 
a) Concentration response curve showing the response of wild-type (NMRI) aorta to bubbling 
with CO gas. Wild-type aorta shows an inhibition of nitrite–dependent vasorelaxation in 
response to CO (n = 5, P < 0.001 by two-way ANOVA). The combined effect of oxypurinol 
and raloxifene is shown for comparison b) Inhibition with CO is not seen in myo
-/-
 aortas, (n 
= 5, P = 0.44 by two-way ANOVA). 
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Figure 7.5. 
 
 
 
 
 
 
Figure 7.5: Replacement of myoglobin to the knockout mouse recapitulates the wild-
type phenotype 
Restitution of myoglobin to myo
-/-
 aorta using a recombinant adenovirus (AdMYO) increases 
vasodilatation to 9 mM sodium nitrite compared to myo
-/-
 aorta treated with control virus 
(AdCtl) (n = 4 for each, P < 0.01). The inhibitory effect of carbon monoxide is restored, *P < 
0.05 by ANOVA 
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Figure 7.6. 
 
 
 
 
 
 
 
 
 
Figure 7.6: Vasorelaxation in the myo
-/-
 mouse is otherwise unimpaired 
Response to the NO-donor SNP is not diminished in myo-/- rings. CO has no effect in 
knockout aortas but increases response to nitrite in wild-type rings, consistent with increased 
scavenging of NO in the presence of myoglobin, *P < 0.05 by ANOVA compared to baseline 
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Figure 7.7. 
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Figure 7.7: Other species contribute to vasorelaxation 
The majority of the remainder of nitrite-dependent vasodilation in myo-/- aorta is due to 
xanthine oxidase and aldehyde dehydrogenase as shown by the addition of specific inhibitors 
(oxypurinol and raloxifene) (n = 4 for each), *P < 0.05 compared to nitrite only, **P < 0.05 
compared to oxypurinol or raloxifene only, and P < 0.001 compared to nitrite only (repeated 
measures ANOVA with post-hoc tests) 
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Figure 7.8. 
a) 
 
b) 
 
 
Figure 7.8: Vasorelaxation by nitrite proceeds through the liberation of NO 
a) 15 minute exposure to 9 mM sodium nitrite causes accumulation of cGMP which was 
lower in myo
-/-
 tissue than wild-type (n = 6 for each), and was prevented by co-administration 
of the NO-scavenger carboxy-PTIO (n = 5); b) Vasorelaxation to 9 mM sodium nitrite is 
prevented by the presence of the NO-scavenger oxyHb and the G-protein inhibitor ODQ (n = 
4 for each). *P < 0.05 compared to control, **P < 0.001 compared to control and myo
-/-
 by 
ANOVA. 
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Figure 7.9. 
a)
 
b) 
 
Figure 7.9: Myoglobin prolongs the duration of vasorelaxation 
a) Incubation of aortic tissue with 20 mM sodium nitrite for 10 minutes produces a prolonged 
vasorelaxation, which persists after removal of sodium nitrite (solid lines: WT, broken lines: 
myo
-/-
) b) The duration of prolonged vasorelaxation is markedly reduced in myo
-/- 
aortas, T(0) 
taken as first time-point where tension reaches baseline (n = 4 for each), *P < 0.05 by two-
tailed t-test 
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Figure 7.10. 
 
 
 
 
 
 
Figure 7.10: A model of myoglobin’s role in vasorelaxation induced by nitrite 
NO is liberated by various species, including myoglobin, xanthine oxidase and ALDH. 
Other heme-containing proteins have a net scavenger role. Exposure to CO inhibits 
myoglobin, reducing vasorelaxation in wild-type aortas, but not in myoglobin-deficient 
aortas, where relief of scavenging is the only effect. 
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Chapter 8 
 
Summary 
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Our understanding of the control of vascular tone, regulation of blood flow and the body’s 
response to injury in the context of ischaemia-reperfusion continues to grow.  It is now 
understood that inorganic nitrite plays an important role in these functions (and potentially 
others).  While its mechanism of action continues to be investigated the physiological 
importance of this anion is being increasingly established.  Exciting therapeutic avenues are 
being explored and sodium nitrite may prove to play a very important pharmacological role in 
conditions including acute myocardial infarction, pulmonary hypertension, coronary artery 
bypass surgery and acute decompensated heart failure. 
 
The studies presented in this thesis have added to our understanding in this area in the 
following ways: 
 
1) We have ascertained that intrabrachial sodium nitrite infusion produces a profound 
venodilatation of the capacitance bed in this hypoxaemic environment. 
2) Under normal physiological conditions, with subjects breathing room air, only a 
modest arteriolar vasodilatation occurs as manifested by a small increase in forearm 
blood flow. However breathing 12% oxygen, rendering the resistance bed 
hypoxaemic, resulted in an exaggerated forearm blood flow response to nitrite 
infusion even at physiological levels of nitrite. 
3) These findings support very strongly that the NO metabolite, sodium nitrite, plays an 
important role in hypoxic vasodilatation. 
4) We have investigated the mechanisms that may lead to nitrite reduction. In vitro 
studies have suggested that NOS and XOR may play a role in the bioconversion of 
nitrite to NO, particularly under severely hypoxic and anoxic conditions.  In healthy 
volunteers, at rest, we did not find that inhibition of these enzymes affected the 
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vascular response to sodium nitrite.  This does not however preclude a role in 
pathological states. 
5) During these studies we have a found the vascular response to nitrite to persist long 
after the plasma levels have returned to near-baseline levels.  This observation may be 
explained by possible protein binding of nitrite or NO and led to studies investigating 
the role of vascular myoglobin.  We demonstrated that myoglobin was present in 
murine aortic rings and that myoglobin knock-out mice manifested a diminished 
nitrite induced vasodilatation.  This response was corrected in the knock-out mice by 
the restoration of myoglobin using a genetically modified adenovirus vector. 
6) We investigated the “translational” implications of these findings.  We have found 
that the pharmacokinetics of nitrite in such patients to be different to that observed in 
healthy volunteers.  Interestingly, although parameters such as pO2 and pH did not 
differ between the groups, at low dose intra-arterial nitrite infusion CHF patients 
manifested an enhanced increase in FBF.  This observation may be explained by 
differences in redox stress and is worthy of further investigation. 
7) We have found systemic intravenous infusion of nitrite to be well tolerated and safe.  
During the breathing of 12% oxygen, nitrite infusion led to reductions in blood 
pressure and total peripheral resistance. 
 
These studies are supportive of an important physiological role for inorganic nitrite and have 
investigated the mechanisms underlying its action.  We were the first to demonstrate the 
critical role of hypoxaemia per se in facilitating nitrite induced vasodilatation in man and 
have investigated the handling of nitrite infusions in patients with heart failure, a group that 
could potentially benefit greatly from its use therapeutically.   
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Figure 8.1: 
Findings of these studies that have advanced our knowledge: 
 
 
 
Nitrite reduction to NO was not affected 
by NOS or XO inhibition
Nitrite induced vasodilatation was 
most profound and was augmented 
by a hypoxaemic environment
Nitrite infusion led to a similar 
venous response in CHF patients but 
produced an exaggerated increase in 
FBF at low dose.
Vascular myoglobin plays a role in 
nitrite reduction and may be involved 
in the prolonged vasodilatatory 
effects of nitrite infusion.
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Recommendations: 
 
Given our knowledge now of the dietary effects of nitrate and nitrite intake future studies 
should control for this variable by defining a suitable and standardised diet prior to any 
experiments.  
 
Further studies should be considered to address the following issues: 
 
1) More detailed “cardiac catheter laboratory” based studies to define accurately the 
effects on cardiac haemodynamics and pulmonary artery pressures and resistance. 
 
2) Given the preferential venodilatation that we observed, studies investigating the effect 
on intravenous nitrite infusion in both acute and chronic decompensated heart failure. 
 
3) The evidence supporting a cytoprotective role for inorganic nitrite provides a strong 
basis for clinical studies investigating the effect of nitrite infusion upon myocardial 
infarction size in the context of patients being treated by primary percutaneous 
coronary intervention. 
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